JPS6326086B2 - - Google Patents
Info
- Publication number
- JPS6326086B2 JPS6326086B2 JP54049832A JP4983279A JPS6326086B2 JP S6326086 B2 JPS6326086 B2 JP S6326086B2 JP 54049832 A JP54049832 A JP 54049832A JP 4983279 A JP4983279 A JP 4983279A JP S6326086 B2 JPS6326086 B2 JP S6326086B2
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine
- amount
- brain
- dopamine
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 113
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 113
- 102000003946 Prolactin Human genes 0.000 claims description 22
- 108010057464 Prolactin Proteins 0.000 claims description 22
- 229940097325 prolactin Drugs 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 18
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 16
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 230000037396 body weight Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 description 78
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 69
- 241001465754 Metazoa Species 0.000 description 51
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 39
- 229960003638 dopamine Drugs 0.000 description 34
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 34
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 29
- 229960003081 probenecid Drugs 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 241000700159 Rattus Species 0.000 description 26
- 229960002748 norepinephrine Drugs 0.000 description 24
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 23
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 229960003878 haloperidol Drugs 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 16
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 15
- 238000009825 accumulation Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 11
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000000225 synapse Anatomy 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- FBWPWWWZWKPJFL-UHFFFAOYSA-N 3-Methoxy-4-hydroxyphenylethyleneglycol Chemical compound COC1=CC(C(O)CO)=CC=C1O FBWPWWWZWKPJFL-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000001577 neostriatum Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000005018 casein Substances 0.000 description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 6
- 235000021240 caseins Nutrition 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- XQQUKAGHLDAJGO-UHFFFAOYSA-N 1-(2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C=C(OC)C=C1O XQQUKAGHLDAJGO-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 3
- 102000015554 Dopamine receptor Human genes 0.000 description 3
- 108050004812 Dopamine receptor Proteins 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 3
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000001640 nerve ending Anatomy 0.000 description 3
- 150000002871 norepinephrines Chemical class 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 3
- 229960003147 reserpine Drugs 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000015115 caffÚ latte Nutrition 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N βâMercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- RQPKNXVVIBYOBX-KDBLBPRBSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-2-(dihydroxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 RQPKNXVVIBYOBX-KDBLBPRBSA-N 0.000 description 1
- GIHYTRGUZVYCQX-UHFFFAOYSA-N 2-amino-6,7-dimethyl-5,6,7,8-tetrahydro-1h-pteridin-4-one;hydron;chloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1NC(C)C(C)N2 GIHYTRGUZVYCQX-UHFFFAOYSA-N 0.000 description 1
- UQTZMGFTRHFAAM-ZETCQYMHSA-N 3-iodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1 UQTZMGFTRHFAAM-ZETCQYMHSA-N 0.000 description 1
- WUFPNASKMLJSND-UHFFFAOYSA-N 3-methoxy-4-hydroxyphenylethyleneglycol sulfate Chemical compound COC1=CC(C(O)CO)=CC=C1OS(O)(=O)=O WUFPNASKMLJSND-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical class O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex⢠Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- -1 but in this case Chemical compound 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 229940095895 haldol Drugs 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- XREXPQGDOPQPAH-QKUPJAQQSA-K trisodium;[(z)-18-[1,3-bis[[(z)-12-sulfonatooxyoctadec-9-enoyl]oxy]propan-2-yloxy]-18-oxooctadec-9-en-7-yl] sulfate Chemical compound [Na+].[Na+].[Na+].CCCCCCC(OS([O-])(=O)=O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O)COC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O XREXPQGDOPQPAH-QKUPJAQQSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
æ¬çºæã¯ãè¡æž
äžã®ããã©ã¯ãã³ã®éãæžå°ã
ããçµæç©ã«é¢ãããã®ã§ããã ç¥çµäŒéç©è³ªã§ãããããã³ããã³ãã«ãšãã
ããªã³ããžããããã·ããšãã«ã¢ã©ãã³ïŒããïŒ
ããèªå°ãããç©è³ªã§ããããšã¯æ¢ã«å ¬ç¥ã§ã
ããäžæ¹ãããã¯ãã¢ããé žã§ããããã·ã³ã®é µ
çŽ åŠçããããã·ã«åã«ãããã€ãã³äžã§çæã
ããã®ã§ããããã®ããã»ã¹ã¯ãé µçŽ ã§ãããã
ã·ã³ããããã·ã©ãŒãŒã®è§Šåªäœçšã®ããšã§é²è¡ã
ããããã¯ãé µçŽ ã§ããâã¢ããé žãã«ã«ãã
ã·ã©ãŒãŒïŒAAADïŒã«ããè±ã«ã«ããã·ã«åã
ããŠãããã³ã«ãªãããã«ãšããããªã³ã¯ãé µçŽ
ã§ãããããã³âβâããããã·ã©ãŒãŒããå«ã
ãã€ãã³äžã§ãããã³ããçããããã®äžé£ã®å
å¿ã«ãããŠãåŸé段éã¯ããã·ã³ãããããžã®å€
æ段éã§ããããã®çç±ã®ããã«ãããŒãã³ãœã³
ç ã®åŠããããã³æ¬ ä¹æ§çŸç ã«èµ·å ãã身äœé害
éšãæããæ£è ã«ãããã³æäžãè¡ãããããšã
ãã€ããããããªããéœåã®æªãããšã«ã¯ããã
ãæäžãããšããã¯èº«äœå šäœã®çŽ°èã«åžåãããŠ
ãããã³ã«å€ãããããã«ãã€ãŠããããã®çŽ°è
ã«ãããæ£åžžãªä»£è¬ããã»ã¹ã劚害ããããšãã
äžéœåãªäºæ ãçããã®ã§ãããããã«ããã¯ã
ç¥çµäŒéç©è³ªã§ããã»ãããã³ã®æ£åžžãªäººäœå è
ç©ã劚害ãããã€ãâã¢ããã·ã«ã¡ããªãã³å
åç©ã®è³å ååšéãäœäžãããããããã®äžææ
ã®å¯äœçšã®ããã«æ£è ã«ããããããªã³âãªãçŸ
象ãçãèªããããããšãããããããŠæå Žåã«
ã¯ç²Ÿç¥ç ç城åãèªããããããšããããåŸãã
ã·ããã¹äžã®ãããã³ããã³ãã«ãšããããªã³ã®
éãå¢å ãããäœçšãæããä»çš®è¬å€ã®äŸã«ã¯ã¢
ãã¢ãã³ãªãã·ããŒãŒæå¶å€ïŒããã¯åèšã®ç¥çµ
äŒéç©è³ªã®å解ãé 延ããããã®ã§ããïŒããã³
ïŒè©²åœ¢ã®ææãã€å€ïŒã¢ã³ãããã¬ãµã³ãïŒãã
ããããããããã®ååç©ã¯æå§çç¶ã䌎ãçŸç
ã®æ²»çå€ãšããŠäœ¿çšãããŠãããããããããŸ
ããã·ããã¹äžã®ãããã³ããã³ãã«ãšããããª
ã³ã®éã®å¢å äœçšã®ä»ã«æ¯èŒçéç¹ç°ã®ååŠçäœ
çšãæãããã®ã§ãã€ãŠãããªãã¡çš®ã ã®å¯äœçš
ãæããããšãã°è¡å§äžæäœçšçãæããããã
ããŠãã®è¡å§äžæã¯ãã¢ãã¢ãã³ãªãã·ããŒãŒæ
å¶å€ãæäžããæ£è ãæçš®ã®é£åãé£ã¹ããšãç
ã«èµ·ããã®ã§ããã ç¥çµäžã®ããã·ã³ã®éãå€ããããšã«ãããã
ãã³ãŸãã¯ãã«ãšããããªã³ã®éãå¢å ãŸãã¯æž
å°ãããè©Šã¿ã以åã«è¡ããããããã®è©Šã¿ã¯æ
åããªãã€ãããªããªãã°è³ããã³çš®ã ã®çµç¹ã®
äžã®ãããã®ååç©ã®éãå€åãããããšã¯è¡ã
ããªãã€ãããã§ãããè³å ã®ããã®æ¿åºŠã¯ãæ
å®ã®å®éšæ¡ä»¶äžã§ã¯ãããã³ããã³ãã«ãšããã
ãªã³ã®åæé床ã«æ¯äŸããŠå€åãããããŠè³å ã®
ããã®æ¿åºŠã¯ãè³å ã®ããã·ã³ã®æ¿åºŠã®å¢å ã«ã
ãå¢å ãããããšãã§ãããã€ãè³å ã®ããã®æ¿
床ã¯ãè³å ã®ããã·ã³ã®æ¿åºŠãäœäžããããããª
åŠçã«ãã€ãŠäœäžãããããšãã§ããïŒã©ããã
çšããå®éšïŒããšãæåã«èŠåºããç 究è ã¯ã¯ãŒ
ããã³çã§ãããããµã€ãšã³ã¹ã第185巻第183é
â第184é ïŒ1974幎ïŒæ12æ¥ïŒããè³å ã®ããã·ã³
ã®éãå¢å ãããããã®åŠçæ¹æ³ã®ïŒã€ã¯ããã
ã·ã³ããèªäœãæäžããããšã§ãã€ããè³å ã®ã
ãã·ã³ã®éãæžå°ãããããã®åŠçæ¹æ³ã®ïŒã€
ã¯ãè¡æŒ¿äžã®ããã·ã³ïŒãã©ãºãããã·ã³ïŒã®è³
å 移è¡æ§ãšç«¶åããæ§è³ªãæããä»çš®äžæ§ã¢ãã
é žã®ãã¡ïŒã€ïŒããšãã°ãã€ã·ã³ïŒãæäžããã
ãšã§ããããã®åŠèª¬ãçºè¡šããã以åã«ã¯ãåèš
ã®åŸé段éã®åå¿ãé²è¡ãããé µçŽ ã§ããããã·
ã³ããããã·ã©ãŒãŒã¯ããã·ã³ã«ããé«åºŠé£œåç¶
æ ã«ãªã€ãŠããã®ã§ãè³å ã®ããã·ã³ã®éã®å¢å
ãŸãã¯æžå°ããããã·ã³ãããããžã®å€æåå¿ã«
圱é¿ãäžããããšã¯ãªãã§ããããšæãããŠãã
ã®ã§ãããäžæ¹ãäžèšã®ã¯ãŒããã³çã®è«æããŸ
ãã¯å ¶åŸã«çºè¡šãããã®ããœã³ããã³ã¯ãŒããã³
ã®è«æããBiochem.Pharmacologyã第26巻第
1137é â第1142é ïŒ1977幎ïŒæå·ïŒãã«ã¯ããã
èç©éã«é¢ããåèšã®å€åã¯ãè³å ã®ãããã³ãŸ
ãã¯ãã«ãšããããªã³ã®éã®å€åã䌎ããã®ã§ã
ãããšã¯å šãé瀺ãããŠããªãããŸããè³å ã®ã
ãã·ã³ã®éãå€ããããšã«ãããã·ããã¹ãžã®ã
ããã³ãŸãã¯ãã«ãšããããªã³ã®æŸåºéã«åœ±é¿ã
äžããããšãã§ããããšããäžèšã®æç®ã«ã¯å šã
é瀺ãããŠããªããæ¬çºæè ã®åºé¡ããç±³åœç¹èš±
åºé¡ç¬¬898740å·æ现æžïŒåºé¡æ¥1978幎ïŒæ24æ¥ïŒ
ã«ã¯ãããã·ã³ã®æäžã«ããã·ããã¹äžã®ããã
ã³ãŸãã¯ãã«ãšããããªã³ãå¢å ãããããšãã§
ããããšãé瀺ãããŠããã ç¥çµæ«ç«¯éšããã®ãããã³ã®æŸåºã劚害ããè¬
å€ãç¥çµæ«ç«¯éšã«ããããããã³ã®çæã劚害ã
ãè¬å€ããŸãã¯ç¥çµæ«ç«¯éšããäžæŠæŸåºãããã
ããã³ã®æŽ»æ§ïŒããªãã¡ãä»ã®çŽ°èäžã®ããã®äŒ
éç©è³ªã®ããã®ã¬ã»ãã¿ãŒãåºæ¿ãã掻æ§ïŒãç¡
ååãããè¬å€ãæäžããåç©ããã³äººäœã§ã¯ã
è¡æž äžã®ããã©ã¯ãã³ïŒè³äžåäœãã«ã¢ã³ã®ïŒ
çš®ïŒã®éãå¢å ããããšãå€ããè¡æž äžã®ããã©
ã¯ãã³ã®éã®å¢å ã¯æãŸãããªãããšã§ãããšæ
ãããããªããªãã°ããã®ãã«ã¢ã³ïŒããªãã¡ã
ãã©ã¯ãã³ïŒã®è¡æž äžå䟡ïŒtitresïŒã®é«ãããš
ãããã«ã¢ã³æææ§è «çã®çºçã®åå ãšãªãããš
ãè¥å¹²ã®è«æã«èšèŒãããŠããããã§ããããŸ
ããèªç¶çºççãªé°èãã€ãããã·ãã¯ã»ã¬ã©ã¯
ãã¬ã¢çïŒidlopathic galactorrheaïŒã®åŠãç
æ°ã®å Žåããããã¯åŸ®çŽ°ãªè³äžåäœè «çïŒããã©
ã¯ãã³ã®çæãä¿é²ããè¬å€ãæçšããŠããªãæ£
è ã«çãããã®ïŒãååšããå Žåã«ããããã©ã¯
ãã³ã®éã®ç çå¢å ãèªããããã æ¬çºæã¯è¡æž äžã®ããã©ã¯ãã³ã®éãæžå°ãã
ãçµæç©ãæäŸãããã®ã§ãããæ¬çºæã«åŸã
ã°ãè¡æž äžã®ããã©ã¯ãã³ã®éãæžå°ããããã€
ãããã³ïŒãŸãã¯ãã«ãšããããªã³ïŒã®éãå¢å
ãããããã«ãããã·ã³ãŸãã¯ãã®ãã¬ã«ãŒãµãŒ
ïŒããªãã¡ããšãã«ã¢ã©ãã³ïŒãåç¬ã§ãããã
ã¯ä»ã®ã¢ããé žãšäžç·ã«ããããã¯çš®ã ã®å»è¬ãš
ã®æ··åç©ã®åœ¢ã§æäžããããšãã§ãããåæ§ã«ã
åèšæ··åç©äžã®ããªãããã¢ã³ïŒããªãã¡ããã
ïŒã€ã®çš®é¡ã®ã¢ããé žïŒã®ååšéïŒååšæ¯çïŒã
çš®ã å€ããããšã«ãããã·ããã¹äžãžã®ã»ããã
ã³ïŒããïŒã€ã®çš®é¡ã®è³ç¥çµäŒéç©è³ªïŒã®æŸåºé
ã調ç¯ã§ããããããã³æŸåºæ§ãã€ãã³ã掻æ§ç¶
æ ã®ãã®ã§ããå Žåãããªãã¡è©²ãã€ãã³ãã²ã
ã±ãã«è奮ãããã®ã§ããå Žåã«ã®ã¿ãããã·ã³
ããã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ã®æäžåŸã«ãã·
ããã¹äžã®ãããã³ã®éãå¢å ããããã®ããš
ã¯ãåèšã®å¿ é ãããã³æŸåºæ§ãã€ãã³äžã«ãã
ãŠãå€éã®ããã©ã¯ãã³ã®ååšäžã«èµ·ããäžæ¹ã
ãã«ãšããããªã³æŸåºæ§ãã€ãã³ã®å Žåã«ã¯ãã
ããç¹ã«æŽ»æ§ã®é«ããã®ã§ãããåŠããšããããš
ãšã¯ç¡é¢ä¿ã«ãããã·ã³ã®æäžã«ãã€ãŠã·ããã¹
äžã®ãã«ãšããããªã³ã®éãå¢å ããããããã®
å Žåã«ãããŠããåèšæäžã«ããè¡æž äžã®ããã©
ã¯ãã³ã®éã¯æžå°ãããå°éæäžã®å Žåã«ã¯ãã
ãã·ã³ã®ä»£ãã«ããšãã«ã¢ã©ãã³ã䜿çšããããš
ãã§ããã æ¬çºæã«åŸãã°ãæ£è ã«ããã·ã³ããã³ïŒãŸã
ã¯ããšãã«ã¢ã©ãã³ãåç¬ã§æäžãããããã¯ã
è¡æž äžã®ããã©ã¯ãã³ã®éãäžæããããšããå¯
äœçšãæããè¬å€ïŒçš®ãŸãã¯ãã以äžãšçµåãã
ãŠæäžããããã«ãã€ãŠè¡æž äžã®ããã©ã¯ãã³ã®
éãæžå°ãããã®ã§ãããããã·ã³ã®æäžã¯ãŸ
ããã·ããã¹äžã®ãããã³ããã³ïŒãŸãã¯ãã«ãš
ããããªã³ã®å¢å ããããããããããã³æŸåºé
ãå¢å ãããããã«ã¯ãæ£è ã®ãããã³æŸåºæ§ã
ã€ãã³ãæ¯èŒçé«æŽ»æ§ã®ãã®ã§ããããšãå¿ èŠã§
ãããããªãã¡ãããŒãã³ãœã³ç ã®æ£è ã®å Žåã®
ããã«ãã°ãã°è奮ãããã®ã§ããããšãå¿ èŠã§
ãããããããªããããã«ãšãããªã³æŸåºæ§ãã€
ãã³ã®å Žåã«ã¯ããããç¹ã«é«æŽ»æ§ã®ãã®ãåŠã
ãšããããšãšã¯ç¡é¢ä¿ã«ãã·ããã¹ãžã®ãã«ãšã
ãããªã³ã®æŸåºéãå¢å ããã®ã§ããã è¡æž äžã®ããã©ã¯ãã³ã®éãæžå°ãããããã«
䜿çšãããæ¬çºæã®çµæç©ã®çµæã¯ãæ²»çãã¹ã
æ£è ã®ç ç¶ã«å¿ããŠé©å®å€ããããšãã§ãããæ£
è ã®è¡æž äžã®ããã©ã¯ãã³ã®éããäžææã®é«ã
å€ã«èªç¶ã«ãªã€ããã®ã§ããå Žåã«ã¯ãããã·ã³
ããã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ãåç¬æäžã®åœ¢
ã§çŽïŒâ200mgïŒKgã奜ãŸããã¯10â100mgïŒKg
ïŒäœéïŒäœ¿çšã§ããããããã¯ãæç æ°ã®æ£è ã
æ²»çããããã«äœ¿çšãããããè¡æž äžã®ããã©ã¯
ãã³ã®éãå¢å ããããšããäžææã®å¯äœçšãæ
ããè¬åã«ä»éãããŠæäžãã圢ã§ãããã·ã³ã
ãã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ãæäžããããšã
å¯èœã§ããããã®ãããªäžææã®å¯äœçšãæãã
è¬å€ã®äŸã«ã¯æ¬¡ã®ãã®ããããããïŒè¡å§éäžå€
ãšããŠæäžãããã¬ã»ã«ãã³ãã¢ã«ãã¡ãããα
âã¡ãã«ãã©ããã·ã³ãã¯ãããžã³ïŒãã©ã³ãã©
ã€ã¶ãŒãšããŠæäžãããããããªããŒã«ããã¢ãž
ãïŒããŒãã³ãœã³ç ã®æ²»çè¬ã§ãã€ãŠãæ«æ¢¢ç³»ã«
ãããâããã®è±ã«ã«ããã·ã«åå¿ã劚害ãã
äœçšãæããã«ã«ãããã®åŠãè¬å€ïŒã¢ãã¢ãã³
ã®ä»£è¬äœçšãå€æ¹ããè¬å€ã§ããææãã€å€ïŒã
ãã©ã¯ãã³ã®åæ³ãä¿é²ãããšã¹ããã²ã³ããã³
ãã®é¢é£ååç©ãæè¬å€ã«ä»éãããŠæäžããå Ž
åã«ã¯ãããã·ã³ããã³ïŒãŸãã¯ããšãã«ã¢ã©ã
ã³ã®æäžéã¯äžè¬ã«çŽïŒâ200mgïŒKgã奜ãŸãã
ã¯çŽ10â100mgïŒKgïŒäœéïŒã§ãããæå Žåã«ã¯
ããã·ã³ã®ä»£çšç©ãšããŠããšãã«ã¢ã©ãã³ã䜿çš
ã§ããããªããªãã°ãã®ã¢ããé žããªãã¡ããšã
ã«ã¢ã©ãã³ã¯èèµã§ããã·ã³ã«å€æããããããŠ
è¡æ¶²æµã®äžã«æŸåºãããŠè³å ã«å ¥ãããã§ããã
ããããªããè¡æŒ¿äžã®ããšãã«ã¢ã©ãã³ã®éã¯ã
ãã·ã³ã®éã®çŽïŒåãããå°ãªãéã§ããã¹ãã§
ããããªããªãã°ããããå€éååšããå Žåã«ã¯
ããšãã«ã¢ã©ãã³ã¯è³å 移è¡æ§ã«é¢ããŠããã·ã³
ãšç«¶åããããã·ã³ããããã·ã©ãŒãŒé µçŽ ã®äœçš
ã劚害ããããšãããåŸãããã§ããã ããã·ã³ããã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ã¯é
é¢ã¢ããé žããšã¹ãã«ãå¡©ã倩ç¶ãŸãã¯åæéå
äœã®åœ¢ã§æäžã§ãããŸãã¯é£ç©ã®æ§ææåã®åœ¢ã§
æäžã§ããããã®æäžã¯ãçµå£æäžãŸãã¯éçµå£
æäžïŒããšãã°éèå æäžïŒã®åœ¢ã§è¡ãããšãã§
ããã æ¬çºæãäžå±€å ·äœçã«äŸç€ºããããã«ã次ã«å®
æœäŸã瀺ããããããªããæ¬çºæã®ç¯å²ã¯æ±ºããŠ
ãããã®å®æœäŸã«èšèŒã®ç¯å²å ã®ã¿éå®ãããã
ã®ã§ã¯ãªãã äŸ ãã®å®æœäŸã¯ãè³å ã§ãã«ãšããããªã³ããè³
å ã®ããã·ã³ã®éãå¢å ãããããšã«ããåæã§
ããããšãäŸç€ºãããã®ã§ããã ãã®å®æœäŸäžã®å®éšããŒã¿ãŒã«ç€ºãããŠããã
ãã«ãè³å ã®ãã«ãšããããªã³ã®äž»ä»£è¬ç£ç©ã§ã
ãïŒâã¡ããã·âïŒâããããã·âããšãã«ãšã
ã¬ã³ã°ãªã³ãŒã«âãµã«ããšãŒãïŒMOPEGâ
SO4ïŒãã©ããã®è³å ã«èç©ãããšãã®èç©é床
ã¯ãè³å ã®ããã·ã³ã®éã®é¢æ°ã®åœ¢ã§çš®ã å€åã
ããã®ã§ããããã®ããšããæãããªããã«è³å
ã®ããã·ã³ã®éã¯ãè³å ã®ãã«ãšããããªã³ã®å
æéã®ã¿ãªããããã®ãã«ãšããããªã³ã®ã¿ãŒã³
ãªãŒããŒéããã³æŸåºéã«ã圱é¿ãäžãããã®ã§
ããã äœé150ïœã®ãªã¹ã®ã¹ãã©ã°ãŒâããŒã¬ã€ã©ã
ãããã€ãŒã«ã¹ããªããŒãããªãŒãžã³ã°ãã©ãã©
ããªãŒãºïŒãŠã€ã«ãã³ã°ãã³ãMAïŒããäŸçµŠã
ãããã®ããã€ãããããã«å ¥ããŠé£Œè²ããïŒïŒ
ããåœãïŒâïŒå¹ïŒããããŠé£²ææ°Žããã³26ïŒ è
çœè³ªé£ŒæïŒãã€ãŒã«ã¹ããªããŒãã©ããâããŠã¹
âãã ã¹ã¿ãŒãã¡ã€ã³ããã³ã¹ãããªãŒããŠã©â
24RFïŒãèªç±ã«äžãããæ¯æ¥ååïŒæããååŸ
ïŒæãŸã§å ç·ã300ãã€ã¯ãã¯ããïŒcm2ïŒãã¿ãŒ
ã©ã€ãããºããŠãŒãã¹ããã³ãŒãã¬ãŒã·ãšã³ïŒã
ãŒã¹ãããŒã²ã³ãN.J.ïŒè£œã®é»çã䜿çšããç §å°
ãããæäžå®éšã®ããã«äœ¿çšãããã©ããã¯ïŒæ©
äžçµ¶é£ããã次ãã§åå10æã«å®éšçšè¬å€æäžå®
éšãéå§ãããã®ããœã³ã®è«æããBiochem.
Pharmacol.ã第26巻第1137é â第1142é ïŒ1977
幎ïŒãã«èšèŒã®è¬å€èª¿è£œæ¹æ³ã«åŸã€ãŠã«ã³ãã³ã²
ã«ïŒæ°Žå35ïœïŒmlïŒãçšããŠçš®ã ã®çµæã®è¬å€ã
調補ãããã¢ããé žããã³è¬åã¯ãã¹ãŠè ¹èå ã«
泚å°ããã è³å ãã€ãã³äžã®ãã«ãšããããªã³ã®åæéã
ãã³ã¿ãŒã³ãªãŒããŒéã次ã®æž¬å®æ¹æ³ã«åŸã€ãŠæž¬
å®ãããããªãã¡ãã®æž¬å®æ¹æ³ã¯ãããããã·ã
ã®æäžåŸã«ããŸãã¯ã©ãããå¯å·ç°å¢äžã«çœ®ãã
åŸã«ãMOPEGâSO4ã®èç©éã枬å®ããããšã
ããªããã®ã§ãã€ããè³ãã¢ãžããŒãäžã®
MOPEGâSO4ããã¢ããªã³äº€æã³ã©ã ããã¢ãŒ
ãã·ã¢ç€ŸïŒãã¹ã«ã¿ãŠãšãŒãN.J.ïŒè£œã®ãâ25
âDEAEâã»ãã¢ããã¯ã¹ãããçšããŠåé¢ããã
ãã®åé¢ã¯ããŒã¯ããã³ããã®æ¹æ³ããBr.J.
Pharmacol.ã第45巻第435é â第441é ïŒ1972
幎ïŒãã«åŸã€ãŠè¡ã€ãããæã ã¯åäžè©Šæã«ãã
ãŠããã·ã³ããã³MOPEGâSO4ã®äž¡è ã枬å®ã§
ããããã«äžèšåé¢æ¹æ³ãæ¹è¯ããŠçšãããåã
ã¢ãžããŒãè©ŠæïŒ0.15MâZnSO4液äžã«å ¥ããã
ã®ïŒã«ã€ããŠãæåã«ããã·ã³ãã¯ãŒã¯ã¹ããã³
ãŠãŒãã³ãã¬ã³ãã®æ¹æ³ããJ.Lab.Mad.ã第50å·»
第733é â第736é ïŒ1957幎ïŒãã«åŸã€ãŠå®éããã
次ãã§ãæ®ãã®ãã¢ãžããŒãã«åœéã®0.15Mâæ°Ž
é žåããªãŠã 液ãæ·»å ããåã³ãã¢ãžãã€ãºã
ãããªã³ã¯ãã³ãã€ã³ã¹ãã«âã¡ã³ã瀟ïŒN.Y.ïŒ
補ã®ãããªããã³ããçšããããé å¿ãåé¢æäœ
ãè¡ãããããŠäžèšã®ã¡ãŒã¯ããã³ããã®æ¹æ³ã«
åŸã€ãŠMOPEGâSO4ãå®éãããè³ãã¢ãžããŒ
ãå šäœããã®MOPEGâSO4ããã³ããã·ã³ã®å
é¢ãååçã¯ãããã70â75ïŒ ããã³85â95ïŒ ã§
ãã€ãã ããã·ã³ãã°ã©ã³ããã¢ã€ã©ã³ãããã€ãªããž
ã«ã«ãã³ã³ãããŒïŒãã³ã°ãã¢ã€ã©ã³ããN.Y.ïŒ
補ã®ãã®ãããã³ããããã·ããã·ã°ããã±ãã«
ã«ãã³ã³ãããŒïŒã»ã³ãã«ã€ã¹ãMOïŒè£œã®ã
ã®ãã¯æ°Žã«é£å®¹æ§ã§ããã®ã§åžNaOH液ã«æº¶è§£
ããåŸãããå溶液ã«å¡©é žãå ããŠç·©è¡äœçšãè¡
ã€ãŠPH7.4ã«å¯Ÿããæ¢ç¥å®¹éã®é£å¡©æ°Žãå ããã
ããã«ãã€ãŠã泚å°æ¶²ãšããŠé©åœãªåŸ®çŽ°æžæ¿æ¶²
ïŒãã¢ã€ã³ããµã¹ãã³ãžãšã³ïŒãåŸãããã å¯å·ç°å¢ã«æŽé²ããããšãã«çããã¹ãã¬ã¹ã«
é¢ããå®éšã§ã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãããã«ãããã·ã³ããèªäœã®ä»£ãã«ãäžå±€æº¶ã
æããšãã«ãšã¹ãã«ã®åœ¢ã®ããã·ã³ãè©Šéšåç©ã«
æäžãããå®éšããŒã¿ãŒã®è§£æã¯ãå€æ°äžå 解æ
æ³ãŸãã¯äºå 解ææ³ã«åŸã€ãŠè¡ã€ãã ããããã·ãã®æäžã«ããè³å ã®MOPEGâ
SO4ã®éãã123nïœïŒïœïŒåžéå€ã®ã¿ã泚å°ãã
å¯Ÿç §åç©ïŒãã175nïœïŒïœãããããã·ãæäž
åç©ãã«å¢å ããïŒïŒ°ïŒ0.001ïŒç¬¬ïŒè¡šïŒããã·
ã³ã®ã¿ã®æäžã¯è³å ã®MOPEGâSO4ã«å šã圱é¿
ãäžããªãã€ããããã®ã¢ããé žãçšããŠååŠç
ãè¡ã€ãå Žåã«ã¯ãããããã·ãã«ããMOPEG
âSO4ã®éã®å¢å 床ãäžå±€å€§ãããªããããªã
ã¡ã175nïœïŒKgïŒããããã·ãã®åç¬æäžãè¡
ã€ãã©ããã®å ŽåïŒãã203nïœïŒïœã«å¢å ãã
ïŒïŒ°ïŒ0.01ïŒç¬¬è¡šïŒã
ããçµæç©ã«é¢ãããã®ã§ããã ç¥çµäŒéç©è³ªã§ãããããã³ããã³ãã«ãšãã
ããªã³ããžããããã·ããšãã«ã¢ã©ãã³ïŒããïŒ
ããèªå°ãããç©è³ªã§ããããšã¯æ¢ã«å ¬ç¥ã§ã
ããäžæ¹ãããã¯ãã¢ããé žã§ããããã·ã³ã®é µ
çŽ åŠçããããã·ã«åã«ãããã€ãã³äžã§çæã
ããã®ã§ããããã®ããã»ã¹ã¯ãé µçŽ ã§ãããã
ã·ã³ããããã·ã©ãŒãŒã®è§Šåªäœçšã®ããšã§é²è¡ã
ããããã¯ãé µçŽ ã§ããâã¢ããé žãã«ã«ãã
ã·ã©ãŒãŒïŒAAADïŒã«ããè±ã«ã«ããã·ã«åã
ããŠãããã³ã«ãªãããã«ãšããããªã³ã¯ãé µçŽ
ã§ãããããã³âβâããããã·ã©ãŒãŒããå«ã
ãã€ãã³äžã§ãããã³ããçããããã®äžé£ã®å
å¿ã«ãããŠãåŸé段éã¯ããã·ã³ãããããžã®å€
æ段éã§ããããã®çç±ã®ããã«ãããŒãã³ãœã³
ç ã®åŠããããã³æ¬ ä¹æ§çŸç ã«èµ·å ãã身äœé害
éšãæããæ£è ã«ãããã³æäžãè¡ãããããšã
ãã€ããããããªããéœåã®æªãããšã«ã¯ããã
ãæäžãããšããã¯èº«äœå šäœã®çŽ°èã«åžåãããŠ
ãããã³ã«å€ãããããã«ãã€ãŠããããã®çŽ°è
ã«ãããæ£åžžãªä»£è¬ããã»ã¹ã劚害ããããšãã
äžéœåãªäºæ ãçããã®ã§ãããããã«ããã¯ã
ç¥çµäŒéç©è³ªã§ããã»ãããã³ã®æ£åžžãªäººäœå è
ç©ã劚害ãããã€ãâã¢ããã·ã«ã¡ããªãã³å
åç©ã®è³å ååšéãäœäžãããããããã®äžææ
ã®å¯äœçšã®ããã«æ£è ã«ããããããªã³âãªãçŸ
象ãçãèªããããããšãããããããŠæå Žåã«
ã¯ç²Ÿç¥ç ç城åãèªããããããšããããåŸãã
ã·ããã¹äžã®ãããã³ããã³ãã«ãšããããªã³ã®
éãå¢å ãããäœçšãæããä»çš®è¬å€ã®äŸã«ã¯ã¢
ãã¢ãã³ãªãã·ããŒãŒæå¶å€ïŒããã¯åèšã®ç¥çµ
äŒéç©è³ªã®å解ãé 延ããããã®ã§ããïŒããã³
ïŒè©²åœ¢ã®ææãã€å€ïŒã¢ã³ãããã¬ãµã³ãïŒãã
ããããããããã®ååç©ã¯æå§çç¶ã䌎ãçŸç
ã®æ²»çå€ãšããŠäœ¿çšãããŠãããããããããŸ
ããã·ããã¹äžã®ãããã³ããã³ãã«ãšããããª
ã³ã®éã®å¢å äœçšã®ä»ã«æ¯èŒçéç¹ç°ã®ååŠçäœ
çšãæãããã®ã§ãã€ãŠãããªãã¡çš®ã ã®å¯äœçš
ãæããããšãã°è¡å§äžæäœçšçãæããããã
ããŠãã®è¡å§äžæã¯ãã¢ãã¢ãã³ãªãã·ããŒãŒæ
å¶å€ãæäžããæ£è ãæçš®ã®é£åãé£ã¹ããšãç
ã«èµ·ããã®ã§ããã ç¥çµäžã®ããã·ã³ã®éãå€ããããšã«ãããã
ãã³ãŸãã¯ãã«ãšããããªã³ã®éãå¢å ãŸãã¯æž
å°ãããè©Šã¿ã以åã«è¡ããããããã®è©Šã¿ã¯æ
åããªãã€ãããªããªãã°è³ããã³çš®ã ã®çµç¹ã®
äžã®ãããã®ååç©ã®éãå€åãããããšã¯è¡ã
ããªãã€ãããã§ãããè³å ã®ããã®æ¿åºŠã¯ãæ
å®ã®å®éšæ¡ä»¶äžã§ã¯ãããã³ããã³ãã«ãšããã
ãªã³ã®åæé床ã«æ¯äŸããŠå€åãããããŠè³å ã®
ããã®æ¿åºŠã¯ãè³å ã®ããã·ã³ã®æ¿åºŠã®å¢å ã«ã
ãå¢å ãããããšãã§ãããã€ãè³å ã®ããã®æ¿
床ã¯ãè³å ã®ããã·ã³ã®æ¿åºŠãäœäžããããããª
åŠçã«ãã€ãŠäœäžãããããšãã§ããïŒã©ããã
çšããå®éšïŒããšãæåã«èŠåºããç 究è ã¯ã¯ãŒ
ããã³çã§ãããããµã€ãšã³ã¹ã第185巻第183é
â第184é ïŒ1974幎ïŒæ12æ¥ïŒããè³å ã®ããã·ã³
ã®éãå¢å ãããããã®åŠçæ¹æ³ã®ïŒã€ã¯ããã
ã·ã³ããèªäœãæäžããããšã§ãã€ããè³å ã®ã
ãã·ã³ã®éãæžå°ãããããã®åŠçæ¹æ³ã®ïŒã€
ã¯ãè¡æŒ¿äžã®ããã·ã³ïŒãã©ãºãããã·ã³ïŒã®è³
å 移è¡æ§ãšç«¶åããæ§è³ªãæããä»çš®äžæ§ã¢ãã
é žã®ãã¡ïŒã€ïŒããšãã°ãã€ã·ã³ïŒãæäžããã
ãšã§ããããã®åŠèª¬ãçºè¡šããã以åã«ã¯ãåèš
ã®åŸé段éã®åå¿ãé²è¡ãããé µçŽ ã§ããããã·
ã³ããããã·ã©ãŒãŒã¯ããã·ã³ã«ããé«åºŠé£œåç¶
æ ã«ãªã€ãŠããã®ã§ãè³å ã®ããã·ã³ã®éã®å¢å
ãŸãã¯æžå°ããããã·ã³ãããããžã®å€æåå¿ã«
圱é¿ãäžããããšã¯ãªãã§ããããšæãããŠãã
ã®ã§ãããäžæ¹ãäžèšã®ã¯ãŒããã³çã®è«æããŸ
ãã¯å ¶åŸã«çºè¡šãããã®ããœã³ããã³ã¯ãŒããã³
ã®è«æããBiochem.Pharmacologyã第26巻第
1137é â第1142é ïŒ1977幎ïŒæå·ïŒãã«ã¯ããã
èç©éã«é¢ããåèšã®å€åã¯ãè³å ã®ãããã³ãŸ
ãã¯ãã«ãšããããªã³ã®éã®å€åã䌎ããã®ã§ã
ãããšã¯å šãé瀺ãããŠããªãããŸããè³å ã®ã
ãã·ã³ã®éãå€ããããšã«ãããã·ããã¹ãžã®ã
ããã³ãŸãã¯ãã«ãšããããªã³ã®æŸåºéã«åœ±é¿ã
äžããããšãã§ããããšããäžèšã®æç®ã«ã¯å šã
é瀺ãããŠããªããæ¬çºæè ã®åºé¡ããç±³åœç¹èš±
åºé¡ç¬¬898740å·æ现æžïŒåºé¡æ¥1978幎ïŒæ24æ¥ïŒ
ã«ã¯ãããã·ã³ã®æäžã«ããã·ããã¹äžã®ããã
ã³ãŸãã¯ãã«ãšããããªã³ãå¢å ãããããšãã§
ããããšãé瀺ãããŠããã ç¥çµæ«ç«¯éšããã®ãããã³ã®æŸåºã劚害ããè¬
å€ãç¥çµæ«ç«¯éšã«ããããããã³ã®çæã劚害ã
ãè¬å€ããŸãã¯ç¥çµæ«ç«¯éšããäžæŠæŸåºãããã
ããã³ã®æŽ»æ§ïŒããªãã¡ãä»ã®çŽ°èäžã®ããã®äŒ
éç©è³ªã®ããã®ã¬ã»ãã¿ãŒãåºæ¿ãã掻æ§ïŒãç¡
ååãããè¬å€ãæäžããåç©ããã³äººäœã§ã¯ã
è¡æž äžã®ããã©ã¯ãã³ïŒè³äžåäœãã«ã¢ã³ã®ïŒ
çš®ïŒã®éãå¢å ããããšãå€ããè¡æž äžã®ããã©
ã¯ãã³ã®éã®å¢å ã¯æãŸãããªãããšã§ãããšæ
ãããããªããªãã°ããã®ãã«ã¢ã³ïŒããªãã¡ã
ãã©ã¯ãã³ïŒã®è¡æž äžå䟡ïŒtitresïŒã®é«ãããš
ãããã«ã¢ã³æææ§è «çã®çºçã®åå ãšãªãããš
ãè¥å¹²ã®è«æã«èšèŒãããŠããããã§ããããŸ
ããèªç¶çºççãªé°èãã€ãããã·ãã¯ã»ã¬ã©ã¯
ãã¬ã¢çïŒidlopathic galactorrheaïŒã®åŠãç
æ°ã®å Žåããããã¯åŸ®çŽ°ãªè³äžåäœè «çïŒããã©
ã¯ãã³ã®çæãä¿é²ããè¬å€ãæçšããŠããªãæ£
è ã«çãããã®ïŒãååšããå Žåã«ããããã©ã¯
ãã³ã®éã®ç çå¢å ãèªããããã æ¬çºæã¯è¡æž äžã®ããã©ã¯ãã³ã®éãæžå°ãã
ãçµæç©ãæäŸãããã®ã§ãããæ¬çºæã«åŸã
ã°ãè¡æž äžã®ããã©ã¯ãã³ã®éãæžå°ããããã€
ãããã³ïŒãŸãã¯ãã«ãšããããªã³ïŒã®éãå¢å
ãããããã«ãããã·ã³ãŸãã¯ãã®ãã¬ã«ãŒãµãŒ
ïŒããªãã¡ããšãã«ã¢ã©ãã³ïŒãåç¬ã§ãããã
ã¯ä»ã®ã¢ããé žãšäžç·ã«ããããã¯çš®ã ã®å»è¬ãš
ã®æ··åç©ã®åœ¢ã§æäžããããšãã§ãããåæ§ã«ã
åèšæ··åç©äžã®ããªãããã¢ã³ïŒããªãã¡ããã
ïŒã€ã®çš®é¡ã®ã¢ããé žïŒã®ååšéïŒååšæ¯çïŒã
çš®ã å€ããããšã«ãããã·ããã¹äžãžã®ã»ããã
ã³ïŒããïŒã€ã®çš®é¡ã®è³ç¥çµäŒéç©è³ªïŒã®æŸåºé
ã調ç¯ã§ããããããã³æŸåºæ§ãã€ãã³ã掻æ§ç¶
æ ã®ãã®ã§ããå Žåãããªãã¡è©²ãã€ãã³ãã²ã
ã±ãã«è奮ãããã®ã§ããå Žåã«ã®ã¿ãããã·ã³
ããã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ã®æäžåŸã«ãã·
ããã¹äžã®ãããã³ã®éãå¢å ããããã®ããš
ã¯ãåèšã®å¿ é ãããã³æŸåºæ§ãã€ãã³äžã«ãã
ãŠãå€éã®ããã©ã¯ãã³ã®ååšäžã«èµ·ããäžæ¹ã
ãã«ãšããããªã³æŸåºæ§ãã€ãã³ã®å Žåã«ã¯ãã
ããç¹ã«æŽ»æ§ã®é«ããã®ã§ãããåŠããšããããš
ãšã¯ç¡é¢ä¿ã«ãããã·ã³ã®æäžã«ãã€ãŠã·ããã¹
äžã®ãã«ãšããããªã³ã®éãå¢å ããããããã®
å Žåã«ãããŠããåèšæäžã«ããè¡æž äžã®ããã©
ã¯ãã³ã®éã¯æžå°ãããå°éæäžã®å Žåã«ã¯ãã
ãã·ã³ã®ä»£ãã«ããšãã«ã¢ã©ãã³ã䜿çšããããš
ãã§ããã æ¬çºæã«åŸãã°ãæ£è ã«ããã·ã³ããã³ïŒãŸã
ã¯ããšãã«ã¢ã©ãã³ãåç¬ã§æäžãããããã¯ã
è¡æž äžã®ããã©ã¯ãã³ã®éãäžæããããšããå¯
äœçšãæããè¬å€ïŒçš®ãŸãã¯ãã以äžãšçµåãã
ãŠæäžããããã«ãã€ãŠè¡æž äžã®ããã©ã¯ãã³ã®
éãæžå°ãããã®ã§ãããããã·ã³ã®æäžã¯ãŸ
ããã·ããã¹äžã®ãããã³ããã³ïŒãŸãã¯ãã«ãš
ããããªã³ã®å¢å ããããããããããã³æŸåºé
ãå¢å ãããããã«ã¯ãæ£è ã®ãããã³æŸåºæ§ã
ã€ãã³ãæ¯èŒçé«æŽ»æ§ã®ãã®ã§ããããšãå¿ èŠã§
ãããããªãã¡ãããŒãã³ãœã³ç ã®æ£è ã®å Žåã®
ããã«ãã°ãã°è奮ãããã®ã§ããããšãå¿ èŠã§
ãããããããªããããã«ãšãããªã³æŸåºæ§ãã€
ãã³ã®å Žåã«ã¯ããããç¹ã«é«æŽ»æ§ã®ãã®ãåŠã
ãšããããšãšã¯ç¡é¢ä¿ã«ãã·ããã¹ãžã®ãã«ãšã
ãããªã³ã®æŸåºéãå¢å ããã®ã§ããã è¡æž äžã®ããã©ã¯ãã³ã®éãæžå°ãããããã«
䜿çšãããæ¬çºæã®çµæç©ã®çµæã¯ãæ²»çãã¹ã
æ£è ã®ç ç¶ã«å¿ããŠé©å®å€ããããšãã§ãããæ£
è ã®è¡æž äžã®ããã©ã¯ãã³ã®éããäžææã®é«ã
å€ã«èªç¶ã«ãªã€ããã®ã§ããå Žåã«ã¯ãããã·ã³
ããã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ãåç¬æäžã®åœ¢
ã§çŽïŒâ200mgïŒKgã奜ãŸããã¯10â100mgïŒKg
ïŒäœéïŒäœ¿çšã§ããããããã¯ãæç æ°ã®æ£è ã
æ²»çããããã«äœ¿çšãããããè¡æž äžã®ããã©ã¯
ãã³ã®éãå¢å ããããšããäžææã®å¯äœçšãæ
ããè¬åã«ä»éãããŠæäžãã圢ã§ãããã·ã³ã
ãã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ãæäžããããšã
å¯èœã§ããããã®ãããªäžææã®å¯äœçšãæãã
è¬å€ã®äŸã«ã¯æ¬¡ã®ãã®ããããããïŒè¡å§éäžå€
ãšããŠæäžãããã¬ã»ã«ãã³ãã¢ã«ãã¡ãããα
âã¡ãã«ãã©ããã·ã³ãã¯ãããžã³ïŒãã©ã³ãã©
ã€ã¶ãŒãšããŠæäžãããããããªããŒã«ããã¢ãž
ãïŒããŒãã³ãœã³ç ã®æ²»çè¬ã§ãã€ãŠãæ«æ¢¢ç³»ã«
ãããâããã®è±ã«ã«ããã·ã«åå¿ã劚害ãã
äœçšãæããã«ã«ãããã®åŠãè¬å€ïŒã¢ãã¢ãã³
ã®ä»£è¬äœçšãå€æ¹ããè¬å€ã§ããææãã€å€ïŒã
ãã©ã¯ãã³ã®åæ³ãä¿é²ãããšã¹ããã²ã³ããã³
ãã®é¢é£ååç©ãæè¬å€ã«ä»éãããŠæäžããå Ž
åã«ã¯ãããã·ã³ããã³ïŒãŸãã¯ããšãã«ã¢ã©ã
ã³ã®æäžéã¯äžè¬ã«çŽïŒâ200mgïŒKgã奜ãŸãã
ã¯çŽ10â100mgïŒKgïŒäœéïŒã§ãããæå Žåã«ã¯
ããã·ã³ã®ä»£çšç©ãšããŠããšãã«ã¢ã©ãã³ã䜿çš
ã§ããããªããªãã°ãã®ã¢ããé žããªãã¡ããšã
ã«ã¢ã©ãã³ã¯èèµã§ããã·ã³ã«å€æããããããŠ
è¡æ¶²æµã®äžã«æŸåºãããŠè³å ã«å ¥ãããã§ããã
ããããªããè¡æŒ¿äžã®ããšãã«ã¢ã©ãã³ã®éã¯ã
ãã·ã³ã®éã®çŽïŒåãããå°ãªãéã§ããã¹ãã§
ããããªããªãã°ããããå€éååšããå Žåã«ã¯
ããšãã«ã¢ã©ãã³ã¯è³å 移è¡æ§ã«é¢ããŠããã·ã³
ãšç«¶åããããã·ã³ããããã·ã©ãŒãŒé µçŽ ã®äœçš
ã劚害ããããšãããåŸãããã§ããã ããã·ã³ããã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ã¯é
é¢ã¢ããé žããšã¹ãã«ãå¡©ã倩ç¶ãŸãã¯åæéå
äœã®åœ¢ã§æäžã§ãããŸãã¯é£ç©ã®æ§ææåã®åœ¢ã§
æäžã§ããããã®æäžã¯ãçµå£æäžãŸãã¯éçµå£
æäžïŒããšãã°éèå æäžïŒã®åœ¢ã§è¡ãããšãã§
ããã æ¬çºæãäžå±€å ·äœçã«äŸç€ºããããã«ã次ã«å®
æœäŸã瀺ããããããªããæ¬çºæã®ç¯å²ã¯æ±ºããŠ
ãããã®å®æœäŸã«èšèŒã®ç¯å²å ã®ã¿éå®ãããã
ã®ã§ã¯ãªãã äŸ ãã®å®æœäŸã¯ãè³å ã§ãã«ãšããããªã³ããè³
å ã®ããã·ã³ã®éãå¢å ãããããšã«ããåæã§
ããããšãäŸç€ºãããã®ã§ããã ãã®å®æœäŸäžã®å®éšããŒã¿ãŒã«ç€ºãããŠããã
ãã«ãè³å ã®ãã«ãšããããªã³ã®äž»ä»£è¬ç£ç©ã§ã
ãïŒâã¡ããã·âïŒâããããã·âããšãã«ãšã
ã¬ã³ã°ãªã³ãŒã«âãµã«ããšãŒãïŒMOPEGâ
SO4ïŒãã©ããã®è³å ã«èç©ãããšãã®èç©é床
ã¯ãè³å ã®ããã·ã³ã®éã®é¢æ°ã®åœ¢ã§çš®ã å€åã
ããã®ã§ããããã®ããšããæãããªããã«è³å
ã®ããã·ã³ã®éã¯ãè³å ã®ãã«ãšããããªã³ã®å
æéã®ã¿ãªããããã®ãã«ãšããããªã³ã®ã¿ãŒã³
ãªãŒããŒéããã³æŸåºéã«ã圱é¿ãäžãããã®ã§
ããã äœé150ïœã®ãªã¹ã®ã¹ãã©ã°ãŒâããŒã¬ã€ã©ã
ãããã€ãŒã«ã¹ããªããŒãããªãŒãžã³ã°ãã©ãã©
ããªãŒãºïŒãŠã€ã«ãã³ã°ãã³ãMAïŒããäŸçµŠã
ãããã®ããã€ãããããã«å ¥ããŠé£Œè²ããïŒïŒ
ããåœãïŒâïŒå¹ïŒããããŠé£²ææ°Žããã³26ïŒ è
çœè³ªé£ŒæïŒãã€ãŒã«ã¹ããªããŒãã©ããâããŠã¹
âãã ã¹ã¿ãŒãã¡ã€ã³ããã³ã¹ãããªãŒããŠã©â
24RFïŒãèªç±ã«äžãããæ¯æ¥ååïŒæããååŸ
ïŒæãŸã§å ç·ã300ãã€ã¯ãã¯ããïŒcm2ïŒãã¿ãŒ
ã©ã€ãããºããŠãŒãã¹ããã³ãŒãã¬ãŒã·ãšã³ïŒã
ãŒã¹ãããŒã²ã³ãN.J.ïŒè£œã®é»çã䜿çšããç §å°
ãããæäžå®éšã®ããã«äœ¿çšãããã©ããã¯ïŒæ©
äžçµ¶é£ããã次ãã§åå10æã«å®éšçšè¬å€æäžå®
éšãéå§ãããã®ããœã³ã®è«æããBiochem.
Pharmacol.ã第26巻第1137é â第1142é ïŒ1977
幎ïŒãã«èšèŒã®è¬å€èª¿è£œæ¹æ³ã«åŸã€ãŠã«ã³ãã³ã²
ã«ïŒæ°Žå35ïœïŒmlïŒãçšããŠçš®ã ã®çµæã®è¬å€ã
調補ãããã¢ããé žããã³è¬åã¯ãã¹ãŠè ¹èå ã«
泚å°ããã è³å ãã€ãã³äžã®ãã«ãšããããªã³ã®åæéã
ãã³ã¿ãŒã³ãªãŒããŒéã次ã®æž¬å®æ¹æ³ã«åŸã€ãŠæž¬
å®ãããããªãã¡ãã®æž¬å®æ¹æ³ã¯ãããããã·ã
ã®æäžåŸã«ããŸãã¯ã©ãããå¯å·ç°å¢äžã«çœ®ãã
åŸã«ãMOPEGâSO4ã®èç©éã枬å®ããããšã
ããªããã®ã§ãã€ããè³ãã¢ãžããŒãäžã®
MOPEGâSO4ããã¢ããªã³äº€æã³ã©ã ããã¢ãŒ
ãã·ã¢ç€ŸïŒãã¹ã«ã¿ãŠãšãŒãN.J.ïŒè£œã®ãâ25
âDEAEâã»ãã¢ããã¯ã¹ãããçšããŠåé¢ããã
ãã®åé¢ã¯ããŒã¯ããã³ããã®æ¹æ³ããBr.J.
Pharmacol.ã第45巻第435é â第441é ïŒ1972
幎ïŒãã«åŸã€ãŠè¡ã€ãããæã ã¯åäžè©Šæã«ãã
ãŠããã·ã³ããã³MOPEGâSO4ã®äž¡è ã枬å®ã§
ããããã«äžèšåé¢æ¹æ³ãæ¹è¯ããŠçšãããåã
ã¢ãžããŒãè©ŠæïŒ0.15MâZnSO4液äžã«å ¥ããã
ã®ïŒã«ã€ããŠãæåã«ããã·ã³ãã¯ãŒã¯ã¹ããã³
ãŠãŒãã³ãã¬ã³ãã®æ¹æ³ããJ.Lab.Mad.ã第50å·»
第733é â第736é ïŒ1957幎ïŒãã«åŸã€ãŠå®éããã
次ãã§ãæ®ãã®ãã¢ãžããŒãã«åœéã®0.15Mâæ°Ž
é žåããªãŠã 液ãæ·»å ããåã³ãã¢ãžãã€ãºã
ãããªã³ã¯ãã³ãã€ã³ã¹ãã«âã¡ã³ã瀟ïŒN.Y.ïŒ
補ã®ãããªããã³ããçšããããé å¿ãåé¢æäœ
ãè¡ãããããŠäžèšã®ã¡ãŒã¯ããã³ããã®æ¹æ³ã«
åŸã€ãŠMOPEGâSO4ãå®éãããè³ãã¢ãžããŒ
ãå šäœããã®MOPEGâSO4ããã³ããã·ã³ã®å
é¢ãååçã¯ãããã70â75ïŒ ããã³85â95ïŒ ã§
ãã€ãã ããã·ã³ãã°ã©ã³ããã¢ã€ã©ã³ãããã€ãªããž
ã«ã«ãã³ã³ãããŒïŒãã³ã°ãã¢ã€ã©ã³ããN.Y.ïŒ
補ã®ãã®ãããã³ããããã·ããã·ã°ããã±ãã«
ã«ãã³ã³ãããŒïŒã»ã³ãã«ã€ã¹ãMOïŒè£œã®ã
ã®ãã¯æ°Žã«é£å®¹æ§ã§ããã®ã§åžNaOH液ã«æº¶è§£
ããåŸãããå溶液ã«å¡©é žãå ããŠç·©è¡äœçšãè¡
ã€ãŠPH7.4ã«å¯Ÿããæ¢ç¥å®¹éã®é£å¡©æ°Žãå ããã
ããã«ãã€ãŠã泚å°æ¶²ãšããŠé©åœãªåŸ®çŽ°æžæ¿æ¶²
ïŒãã¢ã€ã³ããµã¹ãã³ãžãšã³ïŒãåŸãããã å¯å·ç°å¢ã«æŽé²ããããšãã«çããã¹ãã¬ã¹ã«
é¢ããå®éšã§ã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãããã«ãããã·ã³ããèªäœã®ä»£ãã«ãäžå±€æº¶ã
æããšãã«ãšã¹ãã«ã®åœ¢ã®ããã·ã³ãè©Šéšåç©ã«
æäžãããå®éšããŒã¿ãŒã®è§£æã¯ãå€æ°äžå 解æ
æ³ãŸãã¯äºå 解ææ³ã«åŸã€ãŠè¡ã€ãã ããããã·ãã®æäžã«ããè³å ã®MOPEGâ
SO4ã®éãã123nïœïŒïœïŒåžéå€ã®ã¿ã泚å°ãã
å¯Ÿç §åç©ïŒãã175nïœïŒïœãããããã·ãæäž
åç©ãã«å¢å ããïŒïŒ°ïŒ0.001ïŒç¬¬ïŒè¡šïŒããã·
ã³ã®ã¿ã®æäžã¯è³å ã®MOPEGâSO4ã«å šã圱é¿
ãäžããªãã€ããããã®ã¢ããé žãçšããŠååŠç
ãè¡ã€ãå Žåã«ã¯ãããããã·ãã«ããMOPEG
âSO4ã®éã®å¢å 床ãäžå±€å€§ãããªããããªã
ã¡ã175nïœïŒKgïŒããããã·ãã®åç¬æäžãè¡
ã€ãã©ããã®å ŽåïŒãã203nïœïŒïœã«å¢å ãã
ïŒïŒ°ïŒ0.01ïŒç¬¬è¡šïŒã
ãè¡šã
泚ïŒãããã®ïŒã€ã®å®éšã®åã
ã«ãããŠãïŒâ
ïŒå¹ã®ã©ãããïŒã°ã«ãŒãã«ããŠãåã°ã«ãŒãã®
ã©ããã«ãæå®ã®æäžéã®ããã·ã³ïŒè³å ã®ãã
ã®åæãä¿é²ããããšãç¥ãããŠããè¬å€ïŒ100
mgïŒKgãi.p.ïŒãããã¯ãã®åžéå€ã®ã¿ã泚å°ãã
ãããŠ30ååŸã«ããããã·ãïŒ400mgïŒKgãi.p.ïŒ
ãŸãã¯ãã®åžéå€ã®ã¿ã泚å°ããããã®ç¬¬ïŒåç®
ã®æ³šå°ãè¡ã€ãŠãã60ååŸã«è©Šéšåç©ã殺ããã
ã®è³å šäœã«ã€ããŠåæãè¡ã€ãŠããã·ã³ããã³
MOPEGâSO4ã®éã枬å®ãããããã·ã³ã®æäž
ã«ããè³å ã®ããã·ã³ã®éã¯èããå¢å ããïŒïŒ°
±0.001ïŒãäžæ¹ãããããã·ãã¯è³å ã®ããã·ã³
ãå€æ§ãããã®ã§ããªãããŸããå€æ¥ããã·ã³ãž
ã®ãã®ã¬ã¹ãã³ã¹ãå€æ¹ããããã®ã§ããªãã€
ããããããã·ãã¯è³å ã®MOPEGâSO4ã®éã
èããå¢å ããïŒïŒ°Â±0.001ïŒããããŠããã·ã³ã®
ååŠçã«ããããã®ã¬ã¹ãã³ã¹ãèããå¢å€§ãã
ïŒïŒ°Â±0.01ïŒããããã®å®éšããŒã¿ãŒã¯ãå€æ°äºå
解ææ³ã«ãã解æããããããã®å€ã¯ã±SENã
ã§è¡šããããã ã©ãããå¯å·ç°å¢ïŒïŒâïŒäžã«é£Œè²ããå Žåã«
ã¯ãã«ãšããããªã³ã®ã¿ãŒã³ãªãŒããŒéãå¢å
ãããããŠããã«ãã€ãŠãè³å ã®ãã€ãã³äžã®ã
ã«ãšããããªã³èªäœããã³ãã®ä»£è¬ç£ç©
ïŒMOPEGâSO4ïŒã®äž¡è ã®çæãä¿é²ãããã
ã©ãããå¯å·ç°å¢äžã«é£Œè²ããŠæ¬¡ã®ããšã調ã¹
ããããªãã¡ãè³å ã®ããã·ã³ã®éãå€ããåŠç
ã¯ãå¯å·ã¹ãã¬ã¹ãåããã©ããïŒããããã·ã
ãæäžããªãã€ãã©ããïŒã®è³å ã®MOPEGâ
SO4èç©é床ã«åœ±é¿ãäžãããã®ã§ãããã©ãã
調ã¹ãïŒç¬¬ïŒå³ïŒã å¯å·ç°å¢äžã«ïŒæé眮ããšè³å ã®MOPEGâ
SO4ã®éãçŽ40ïŒ å¢å ããïŒããªãã¡ãã®éã¯
80nïœïŒïœãã11nïœïŒïœã«å¢å ããïŒïŒ°ïŒ
0.001ïŒãã¢ããé žãŸãã¯é£å¡©æ°Žã®ãããããæäž
ããè©Šéšåç©ã§ã¯ãè³å ã®ããã·ã³ã®éã¯å€§äœå
ãã§ããããã€ããã¯MOPEGâSO4ã®éã«å¯æ¥
ã«é¢é£ãããã®ã§ãã€ããïŒïœïŒ77ïŒïŒ°ïŒ0.05ïŒ
第ïŒå³ïŒãããã·ã³æäžã«ããååŠçã«ããè³å
ã®ããã·ã³ã®éãçŽ80ïŒ å¢å ããããªãã¡ã
13.3ÎŒïœïŒïœïŒé£å¡©æ°Žã泚å°ããåç©ã®å ŽåïŒã
ã24.6ÎŒïœïŒïœã«å¢å ããïŒïŒ°ïŒ0.01ããMOPEG
âSO4ã®éã¯çŽ70ïŒ å¢å ããïŒããªãã¡ã114n
ïœïŒïœãã193nïœïŒïœã«å¢å ããïŒïŒ°ïŒ0.01ïŒã
ãã®å®éšã§ã¯ããªã³ã®æäžã«ããååŠçãè¡ã€ã
ãããã®å Žåã«ã¯è³å ã®ããã·ã³ãŸãã¯MOPEG
âSO4ã®éã¯å®è³ªçã«ç¡å€åã§ãã€ãïŒããªãã¡
ãã®ïŒã€ã®éã¯ãããã14.3ÎŒïœïŒïœããã³117n
ïœïŒïœã§ãã€ãïŒãããããªãããä»ã®ã°ã«ãŒã
ã«å¯Ÿããå®éšã®çµæïŒç¬¬ïŒå³ïŒããæãããªãã
ã«ãè³å ã®ããã·ã³ããã³MOPEGâSO4ã®é
ã¯ãè©Šéšåç©èªäœãšãå¯æ¥ã«é¢é£ãããã®ã§ãã€
ãã 第ïŒå³èšèŒã®çžé¢é¢ä¿ã¯æ¬¡ã®å®éšã§åŸãããã
ã®ã§ãã€ããè€æ°ã®ã°ã«ãŒãã®ã©ããã®åã ã®è ¹
èå ã«ããªã³ïŒ200mgïŒKgïŒããŸãã¯ãè³å åžåæ§
ã«é¢ããŠããã·ã³ãšç«¶åããæ§è³ªãæããã¢ãã
é žïŒïŒïŒããŸãã¯ããã·ã³ïŒãšãã«ãšã¹ãã«ã®åœ¢
ã®ããã·ã³125mgïŒKgïŒããŸãã¯é£å¡©æ°Žã泚å°ã
ãã30ååŸã«ãã®ã©ãããã·ã³ã°ã«ã±ãŒãžïŒã
ãïŒã«å ¥ããŠå¯å·ç°å¢ïŒïŒâïŒäžã«çœ®ãããïŒæ
éåŸã«è©Šéšåç©ãå šéšæ®ºãããã®è¡æ¶²å šéšã«ã€ã
ãŠåæãè¡ã€ãŠããã·ã³ããã³MOPEGâSO4ã®
éã枬å®ãããå¯Ÿç §åç©ã«ã¯é£å¡©ã泚å°ããã·ã³
ã°ã«ã±ãŒãžã«å ¥ããŠå®€æž©ïŒ22âïŒã«ãããŠ90åé
ä¿ã€ããã°ã©ãäžã®åç¹ã¯ïŒã€ã®è³ã®äžã«ååšã
ãããã·ã³ããã³MOPEGâSO4ã®éãè¡šããã
ãããã®ããŒã¿ãŒã¯ãè¥å¹²ã®å®éšçµæãéèšããŠ
ç®åºããããã®ã§ãã€ãã宀枩ã«ãããŠé£Œè²ãã
ãè©Šéšåç©ã®è³å ã®ããã·ã³ããã³MOPEGâ
SO4ã®éã¯ãããã14.6ÎŒïœããã³80nïœïŒïœã§ã
ã€ãã第ïŒå³ã®ã°ã©ãã«ãããŠãå笊å·ã¯æ¬¡ã®æ
å³ãæããïŒé»äžžâŠâŠããªã³ã§ååŠçãããåç©
ã«ããã枬å®å€ïŒçœäžžâŠâŠé£å¡©æ°Žã§ååŠçããã
åç©ã«ããã枬å®å€ïŒçœãåè§âŠâŠããã·ã³ã§å
åŠçãããåç©ã«ããã枬å®å€ã è³å ã®ããã·ã³ã®éã®ççåŠçãã©ããããŸ
ãããã«ãšããããªã³ã®åæéããã³ã¿ãŒã³ãªãŒ
ããŒéïŒããã¯ãMOPEGâSO4ã®éã®æž¬å®ã«ã
ã枬å®ã§ããïŒã«åœ±é¿ãäžãããã®ã§ãããã©ã
ããã¿ãããã«ã次ã®å®éšãè¡ã€ããããªãã¡ã
å¯å·ç°å¢äžã«çœ®ããè©Šéšåç©ã«ãããäžèšã®ä»£è¬
ç£ç©ã®èç©éã調ã¹ãæäœããããã·ã³ã®éãé«
ããæãããåçŽé£ŒæïŒsingle mealïŒãé£ã¹ã
ããåŸã«è¡ã€ãã ïŒæ©äžçµ¶é£ãããè©Šéšåç©ã«ç¡èçœé£ŒæïŒã«ãŒ
ã€ã³ïŒïŒ ïŒãŸãã¯40ïŒ ã«ãŒã€ã³é£Œæãåå10æã
ãåå11æãŸã§ã®æéã«ããã€ãŠäžãã次ãã§è©Š
éšåç©ãå¯å·ç°å¢ïŒïŒâïŒäžã«ïŒæéä¿ã¡ã次ã
ã§ããã殺ãããã®è³ãåæããŠããã·ã³ããã³
MOPEGâSO4ã®éã枬å®ããã絶é£ãããå¯Ÿç §
åç©ã¯ããã®ïŒæéã«ããã€ãŠå®€æž©ïŒ22âïŒã«ã
ããŠä¿ã€ãã 絶é£ãããã©ãããå¯å·ç°å¢äžã«ä¿ã€ããšã«ã
ãããã®è³å ã®MOPEGâSO4ã®èç©ãä¿é²ã§
ãããã®éã¯123nïœïŒ22âã«ãããŠä¿ããã絶
é£å¯Ÿè±¡åç©ïŒãã163nïœã«å¢å ããïŒïŒ°ïŒ0.05ïŒã
ãã®åŠçã¯è³å ã®ããã·ã³ã®éã«ã¯å šã圱é¿ãäž
ããªãã€ãïŒ10.1ÎŒïœïŒïœå¯Ÿ10.5ÎŒïœïŒïœïŒãå¯å·
ç°å¢äžã«çœ®ãããåç©ã®ãã¡ã§ãïŒïŒ ã«ãŒã€ã³é£Œ
æãŸãã¯40ïŒ ã«ãŒã€ã³é£Œæãæäžããåç©ã§ã¯ã
è³å ã®MOPEGâSO4ã®èç©éã40â50ïŒ å¢å ã
ãïŒç¬¬è¡šïŒïŒ°ïŒ0.01ïŒãïŒïŒ ã«ãŒã€ã³é£Œæãæ
äžããåç©ã§ã¯è³å ã®ããã·ã³ã®éã40ïŒ å¢å ã
ïŒïŒ°ïŒ0.01ïŒãäžæ¹ã40ïŒ ã«ãŒã€ã³é£Œæãé£ã¹ãå
ç©ã§ã¯è³å ã®ããã·ã³ã®éã77ïŒ å¢å ããïŒïŒ°ïŒ
0.01ïŒã ç¡èçœè³ªé£Œæã®æäžãè³å ã®ããã·ã³ã®éã®å¢
å ããããããªãã€ãå Žåã«ã¯ãè³å ã®MOPEG
âSO4ã®éããŸãå¢å ããªãã€ãïŒç¬¬è¡šïŒãã
ã®å®éšã«ãããŠãèçœè³ªãæäžããåç©ã§ã¯è³å
ã®ããã·ã³ã®éãçŽ50ïŒ å¢å ãïŒããªãã¡ã
13.4ÎŒïœïŒïœãã19.5ÎŒïœïŒïœã«å¢å ããïŒïŒ°ïŒ
0.01ïŒããã€ããã«äžŠè¡ããŠè³å ã®MOPEGâSO4
ã®éãå¢å ããã ãããã®å®éšããŒã¿ãŒããæãããªããã«ãã
ãããã·ãã§ååŠçããããŸãã¯å¯å·ç°å¢äžã«çœ®
ããã©ããã§ã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãåŠçãè¡ãããšã«ãããè³å ã®ãã«ãšããããª
ã³ã®ä»£è¬ç£ç©ã§ããMOPEGâSO4ã®èç©éãå¢
å ãããããšãã§ããã®ã§ããããã®ãããªåŠç
ã¯è¬çåŠçåŠçïŒããªãã¡ãããã·ã³ã®è ¹èå 泚
å°ïŒãŸãã¯ççåŠçåŠçïŒããªãã¡ãé«èçœè³ªé£Œ
æã®æäžïŒã§ãã€ãŠããããããã®åŠçã¯ãè³å
ã®ããã·ã³æ¿åºŠã«é¢ããŠããã®åºè³ªïŒãµãã¹ãã¬
ãŒãã®ããã®ããã·ã³ããããã·ã©ãŒãŒã®é«Km
æ§ã«å¹æµããå¹æãäžãããã®ã§ããããã®é µçŽ
ã¯ãåºè³ªã«ã€ããŠå¶éæ¡ä»¶ããããšããæ¬ ç¹ãæ
ããããªããªãã°ããã®é µçŽ ã掻æ§åããããšã
ã«ããã®æŽ»æ§ãããã®ã³ãã¢ã¯ã¿ãŒã«å¯Ÿãã芪å
æ§ãéžæçã«é«ããããã§ããã MOPEGâSO4ã¯ã©ããã®è³å ã«ããããã«ãš
ããããªã³ã®äž»ä»£è¬ç£ç©ã§ãã€ãŠãããã¯ããã
ããã·ãã«ææãªã¡ã«ããºã ã«ããè³å€ã«éã³åº
ããããããããã·ãã®æäžåŸã«ã¯MOPEGâ
SO4ã¯ã©ããã®è³å ã«ãå°ãªããšã60åéã«ãã
ã€ãŠãæéã«çŽç·çã«æ¯äŸããéçå²åã§èç©ã
ãããã®æéã®éã¯è³å ã®ãã«ãšããããªã³ã®é
ã¯äžå€ç¶æ ã®ãŸãŸä¿ãããŠãããããMOPEGâ
SO4ã®èç©çïŒèç©éïŒã¯ããã«ãšããããªã³ã®
åæçã瀺ãæçšãªææšãšããŠåœ¹ç«ã€ãã®ã§ã
ãããã®èç©çã¯ãã¹ãã¬ã¹ãäžããã«ãããã
ã·ãåŠçãè¡ã€ãã©ããã®å Žåã«ã¯ãå¯å·ç°å¢äž
ã«çœ®ãããã©ããã®å Žåãããæããã«äœãã€ã
ïŒç¬¬è¡šããã³ç¬¬ïŒãããããªãããã©ãããã
ã®ïŒã€ã®ç°å¢ã®ãã¡ã®ãããã®ç°å¢ã®ããšã§çœ®ã
ãå Žåã§ããäžèšã®èç©çã¯è³å ã®ããã·ã³ã®é
ã«å·Šå³ãããå€ã§ããã
ïŒå¹ã®ã©ãããïŒã°ã«ãŒãã«ããŠãåã°ã«ãŒãã®
ã©ããã«ãæå®ã®æäžéã®ããã·ã³ïŒè³å ã®ãã
ã®åæãä¿é²ããããšãç¥ãããŠããè¬å€ïŒ100
mgïŒKgãi.p.ïŒãããã¯ãã®åžéå€ã®ã¿ã泚å°ãã
ãããŠ30ååŸã«ããããã·ãïŒ400mgïŒKgãi.p.ïŒ
ãŸãã¯ãã®åžéå€ã®ã¿ã泚å°ããããã®ç¬¬ïŒåç®
ã®æ³šå°ãè¡ã€ãŠãã60ååŸã«è©Šéšåç©ã殺ããã
ã®è³å šäœã«ã€ããŠåæãè¡ã€ãŠããã·ã³ããã³
MOPEGâSO4ã®éã枬å®ãããããã·ã³ã®æäž
ã«ããè³å ã®ããã·ã³ã®éã¯èããå¢å ããïŒïŒ°
±0.001ïŒãäžæ¹ãããããã·ãã¯è³å ã®ããã·ã³
ãå€æ§ãããã®ã§ããªãããŸããå€æ¥ããã·ã³ãž
ã®ãã®ã¬ã¹ãã³ã¹ãå€æ¹ããããã®ã§ããªãã€
ããããããã·ãã¯è³å ã®MOPEGâSO4ã®éã
èããå¢å ããïŒïŒ°Â±0.001ïŒããããŠããã·ã³ã®
ååŠçã«ããããã®ã¬ã¹ãã³ã¹ãèããå¢å€§ãã
ïŒïŒ°Â±0.01ïŒããããã®å®éšããŒã¿ãŒã¯ãå€æ°äºå
解ææ³ã«ãã解æããããããã®å€ã¯ã±SENã
ã§è¡šããããã ã©ãããå¯å·ç°å¢ïŒïŒâïŒäžã«é£Œè²ããå Žåã«
ã¯ãã«ãšããããªã³ã®ã¿ãŒã³ãªãŒããŒéãå¢å
ãããããŠããã«ãã€ãŠãè³å ã®ãã€ãã³äžã®ã
ã«ãšããããªã³èªäœããã³ãã®ä»£è¬ç£ç©
ïŒMOPEGâSO4ïŒã®äž¡è ã®çæãä¿é²ãããã
ã©ãããå¯å·ç°å¢äžã«é£Œè²ããŠæ¬¡ã®ããšã調ã¹
ããããªãã¡ãè³å ã®ããã·ã³ã®éãå€ããåŠç
ã¯ãå¯å·ã¹ãã¬ã¹ãåããã©ããïŒããããã·ã
ãæäžããªãã€ãã©ããïŒã®è³å ã®MOPEGâ
SO4èç©é床ã«åœ±é¿ãäžãããã®ã§ãããã©ãã
調ã¹ãïŒç¬¬ïŒå³ïŒã å¯å·ç°å¢äžã«ïŒæé眮ããšè³å ã®MOPEGâ
SO4ã®éãçŽ40ïŒ å¢å ããïŒããªãã¡ãã®éã¯
80nïœïŒïœãã11nïœïŒïœã«å¢å ããïŒïŒ°ïŒ
0.001ïŒãã¢ããé žãŸãã¯é£å¡©æ°Žã®ãããããæäž
ããè©Šéšåç©ã§ã¯ãè³å ã®ããã·ã³ã®éã¯å€§äœå
ãã§ããããã€ããã¯MOPEGâSO4ã®éã«å¯æ¥
ã«é¢é£ãããã®ã§ãã€ããïŒïœïŒ77ïŒïŒ°ïŒ0.05ïŒ
第ïŒå³ïŒãããã·ã³æäžã«ããååŠçã«ããè³å
ã®ããã·ã³ã®éãçŽ80ïŒ å¢å ããããªãã¡ã
13.3ÎŒïœïŒïœïŒé£å¡©æ°Žã泚å°ããåç©ã®å ŽåïŒã
ã24.6ÎŒïœïŒïœã«å¢å ããïŒïŒ°ïŒ0.01ããMOPEG
âSO4ã®éã¯çŽ70ïŒ å¢å ããïŒããªãã¡ã114n
ïœïŒïœãã193nïœïŒïœã«å¢å ããïŒïŒ°ïŒ0.01ïŒã
ãã®å®éšã§ã¯ããªã³ã®æäžã«ããååŠçãè¡ã€ã
ãããã®å Žåã«ã¯è³å ã®ããã·ã³ãŸãã¯MOPEG
âSO4ã®éã¯å®è³ªçã«ç¡å€åã§ãã€ãïŒããªãã¡
ãã®ïŒã€ã®éã¯ãããã14.3ÎŒïœïŒïœããã³117n
ïœïŒïœã§ãã€ãïŒãããããªãããä»ã®ã°ã«ãŒã
ã«å¯Ÿããå®éšã®çµæïŒç¬¬ïŒå³ïŒããæãããªãã
ã«ãè³å ã®ããã·ã³ããã³MOPEGâSO4ã®é
ã¯ãè©Šéšåç©èªäœãšãå¯æ¥ã«é¢é£ãããã®ã§ãã€
ãã 第ïŒå³èšèŒã®çžé¢é¢ä¿ã¯æ¬¡ã®å®éšã§åŸãããã
ã®ã§ãã€ããè€æ°ã®ã°ã«ãŒãã®ã©ããã®åã ã®è ¹
èå ã«ããªã³ïŒ200mgïŒKgïŒããŸãã¯ãè³å åžåæ§
ã«é¢ããŠããã·ã³ãšç«¶åããæ§è³ªãæããã¢ãã
é žïŒïŒïŒããŸãã¯ããã·ã³ïŒãšãã«ãšã¹ãã«ã®åœ¢
ã®ããã·ã³125mgïŒKgïŒããŸãã¯é£å¡©æ°Žã泚å°ã
ãã30ååŸã«ãã®ã©ãããã·ã³ã°ã«ã±ãŒãžïŒã
ãïŒã«å ¥ããŠå¯å·ç°å¢ïŒïŒâïŒäžã«çœ®ãããïŒæ
éåŸã«è©Šéšåç©ãå šéšæ®ºãããã®è¡æ¶²å šéšã«ã€ã
ãŠåæãè¡ã€ãŠããã·ã³ããã³MOPEGâSO4ã®
éã枬å®ãããå¯Ÿç §åç©ã«ã¯é£å¡©ã泚å°ããã·ã³
ã°ã«ã±ãŒãžã«å ¥ããŠå®€æž©ïŒ22âïŒã«ãããŠ90åé
ä¿ã€ããã°ã©ãäžã®åç¹ã¯ïŒã€ã®è³ã®äžã«ååšã
ãããã·ã³ããã³MOPEGâSO4ã®éãè¡šããã
ãããã®ããŒã¿ãŒã¯ãè¥å¹²ã®å®éšçµæãéèšããŠ
ç®åºããããã®ã§ãã€ãã宀枩ã«ãããŠé£Œè²ãã
ãè©Šéšåç©ã®è³å ã®ããã·ã³ããã³MOPEGâ
SO4ã®éã¯ãããã14.6ÎŒïœããã³80nïœïŒïœã§ã
ã€ãã第ïŒå³ã®ã°ã©ãã«ãããŠãå笊å·ã¯æ¬¡ã®æ
å³ãæããïŒé»äžžâŠâŠããªã³ã§ååŠçãããåç©
ã«ããã枬å®å€ïŒçœäžžâŠâŠé£å¡©æ°Žã§ååŠçããã
åç©ã«ããã枬å®å€ïŒçœãåè§âŠâŠããã·ã³ã§å
åŠçãããåç©ã«ããã枬å®å€ã è³å ã®ããã·ã³ã®éã®ççåŠçãã©ããããŸ
ãããã«ãšããããªã³ã®åæéããã³ã¿ãŒã³ãªãŒ
ããŒéïŒããã¯ãMOPEGâSO4ã®éã®æž¬å®ã«ã
ã枬å®ã§ããïŒã«åœ±é¿ãäžãããã®ã§ãããã©ã
ããã¿ãããã«ã次ã®å®éšãè¡ã€ããããªãã¡ã
å¯å·ç°å¢äžã«çœ®ããè©Šéšåç©ã«ãããäžèšã®ä»£è¬
ç£ç©ã®èç©éã調ã¹ãæäœããããã·ã³ã®éãé«
ããæãããåçŽé£ŒæïŒsingle mealïŒãé£ã¹ã
ããåŸã«è¡ã€ãã ïŒæ©äžçµ¶é£ãããè©Šéšåç©ã«ç¡èçœé£ŒæïŒã«ãŒ
ã€ã³ïŒïŒ ïŒãŸãã¯40ïŒ ã«ãŒã€ã³é£Œæãåå10æã
ãåå11æãŸã§ã®æéã«ããã€ãŠäžãã次ãã§è©Š
éšåç©ãå¯å·ç°å¢ïŒïŒâïŒäžã«ïŒæéä¿ã¡ã次ã
ã§ããã殺ãããã®è³ãåæããŠããã·ã³ããã³
MOPEGâSO4ã®éã枬å®ããã絶é£ãããå¯Ÿç §
åç©ã¯ããã®ïŒæéã«ããã€ãŠå®€æž©ïŒ22âïŒã«ã
ããŠä¿ã€ãã 絶é£ãããã©ãããå¯å·ç°å¢äžã«ä¿ã€ããšã«ã
ãããã®è³å ã®MOPEGâSO4ã®èç©ãä¿é²ã§
ãããã®éã¯123nïœïŒ22âã«ãããŠä¿ããã絶
é£å¯Ÿè±¡åç©ïŒãã163nïœã«å¢å ããïŒïŒ°ïŒ0.05ïŒã
ãã®åŠçã¯è³å ã®ããã·ã³ã®éã«ã¯å šã圱é¿ãäž
ããªãã€ãïŒ10.1ÎŒïœïŒïœå¯Ÿ10.5ÎŒïœïŒïœïŒãå¯å·
ç°å¢äžã«çœ®ãããåç©ã®ãã¡ã§ãïŒïŒ ã«ãŒã€ã³é£Œ
æãŸãã¯40ïŒ ã«ãŒã€ã³é£Œæãæäžããåç©ã§ã¯ã
è³å ã®MOPEGâSO4ã®èç©éã40â50ïŒ å¢å ã
ãïŒç¬¬è¡šïŒïŒ°ïŒ0.01ïŒãïŒïŒ ã«ãŒã€ã³é£Œæãæ
äžããåç©ã§ã¯è³å ã®ããã·ã³ã®éã40ïŒ å¢å ã
ïŒïŒ°ïŒ0.01ïŒãäžæ¹ã40ïŒ ã«ãŒã€ã³é£Œæãé£ã¹ãå
ç©ã§ã¯è³å ã®ããã·ã³ã®éã77ïŒ å¢å ããïŒïŒ°ïŒ
0.01ïŒã ç¡èçœè³ªé£Œæã®æäžãè³å ã®ããã·ã³ã®éã®å¢
å ããããããªãã€ãå Žåã«ã¯ãè³å ã®MOPEG
âSO4ã®éããŸãå¢å ããªãã€ãïŒç¬¬è¡šïŒãã
ã®å®éšã«ãããŠãèçœè³ªãæäžããåç©ã§ã¯è³å
ã®ããã·ã³ã®éãçŽ50ïŒ å¢å ãïŒããªãã¡ã
13.4ÎŒïœïŒïœãã19.5ÎŒïœïŒïœã«å¢å ããïŒïŒ°ïŒ
0.01ïŒããã€ããã«äžŠè¡ããŠè³å ã®MOPEGâSO4
ã®éãå¢å ããã ãããã®å®éšããŒã¿ãŒããæãããªããã«ãã
ãããã·ãã§ååŠçããããŸãã¯å¯å·ç°å¢äžã«çœ®
ããã©ããã§ã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãåŠçãè¡ãããšã«ãããè³å ã®ãã«ãšããããª
ã³ã®ä»£è¬ç£ç©ã§ããMOPEGâSO4ã®èç©éãå¢
å ãããããšãã§ããã®ã§ããããã®ãããªåŠç
ã¯è¬çåŠçåŠçïŒããªãã¡ãããã·ã³ã®è ¹èå 泚
å°ïŒãŸãã¯ççåŠçåŠçïŒããªãã¡ãé«èçœè³ªé£Œ
æã®æäžïŒã§ãã€ãŠããããããã®åŠçã¯ãè³å
ã®ããã·ã³æ¿åºŠã«é¢ããŠããã®åºè³ªïŒãµãã¹ãã¬
ãŒãã®ããã®ããã·ã³ããããã·ã©ãŒãŒã®é«Km
æ§ã«å¹æµããå¹æãäžãããã®ã§ããããã®é µçŽ
ã¯ãåºè³ªã«ã€ããŠå¶éæ¡ä»¶ããããšããæ¬ ç¹ãæ
ããããªããªãã°ããã®é µçŽ ã掻æ§åããããšã
ã«ããã®æŽ»æ§ãããã®ã³ãã¢ã¯ã¿ãŒã«å¯Ÿãã芪å
æ§ãéžæçã«é«ããããã§ããã MOPEGâSO4ã¯ã©ããã®è³å ã«ããããã«ãš
ããããªã³ã®äž»ä»£è¬ç£ç©ã§ãã€ãŠãããã¯ããã
ããã·ãã«ææãªã¡ã«ããºã ã«ããè³å€ã«éã³åº
ããããããããã·ãã®æäžåŸã«ã¯MOPEGâ
SO4ã¯ã©ããã®è³å ã«ãå°ãªããšã60åéã«ãã
ã€ãŠãæéã«çŽç·çã«æ¯äŸããéçå²åã§èç©ã
ãããã®æéã®éã¯è³å ã®ãã«ãšããããªã³ã®é
ã¯äžå€ç¶æ ã®ãŸãŸä¿ãããŠãããããMOPEGâ
SO4ã®èç©çïŒèç©éïŒã¯ããã«ãšããããªã³ã®
åæçã瀺ãæçšãªææšãšããŠåœ¹ç«ã€ãã®ã§ã
ãããã®èç©çã¯ãã¹ãã¬ã¹ãäžããã«ãããã
ã·ãåŠçãè¡ã€ãã©ããã®å Žåã«ã¯ãå¯å·ç°å¢äž
ã«çœ®ãããã©ããã®å Žåãããæããã«äœãã€ã
ïŒç¬¬è¡šããã³ç¬¬ïŒãããããªãããã©ãããã
ã®ïŒã€ã®ç°å¢ã®ãã¡ã®ãããã®ç°å¢ã®ããšã§çœ®ã
ãå Žåã§ããäžèšã®èç©çã¯è³å ã®ããã·ã³ã®é
ã«å·Šå³ãããå€ã§ããã
ãè¡šã
ãŒã€ã³ïŒ
ãè¡šã
泚ïŒïŒâïŒå¹ã®ã©ãããïŒã°ã«ãŒããšããè€æ°
ã®ã°ã«ãŒãã®ã©ãããïŒæ©äžé£Œæãäžããã次ã
ã§è©Šéšé£Œæã®ãã¡ã®ïŒã€ãåå10æã«äžãããå
å11æããããã®è©Šéšåç©ãïŒâã®å¯å·ç°å¢ã®å®€
ã«ïŒæéå ¥ãããæ£åã«ãã®è©Šéšåç©ã殺ããã
ã®è³å šäœãåæããŠããã·ã³ããã³MOPEGâ
SO4ã®éã枬å®ãããå®éšã§ã¯ãè©Šéšåç©ã¯ç¡
èçœè³ªé£ŒæãŸãã¯40ïŒ èçœè³ªé£Œæããããã9.7
ïœãŸãã¯10.5ïœæ¶è²»ããå®éšã«ããããããã®
飌æã®æ¶è²»éã¯ãããã6.2ïœãŸãã¯8.0ïœã§ãã€
ãããã®ããŒã¿ã¯ã±SEMã®å¹³åå€ãšããŠç®åºã
ãããã®ã§ãã€ãã äŸ ãã®å®æœäŸã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãããšã«ããè³å ã®ãããã³æŸåºéãå¢å ã§ãã
ããšãäŸç€ºãããã®ã§ããã ãã®ããã·ã³ã®ååšéã®å€å°ãã«ãã³ãŒã«ã¢ã
ã³ç¥çµäŒéç©è³ªã®ã·ããã¹å æŸåºéã«åœ±é¿ãäžã
ããã®ã§ãããã©ãããã¿ãããã«ãè©Šéšåç©ã®
è³å ã«ããããããã³ä»£è¬ç£ç©ã§ãããã¢ãããª
ã³é žïŒHVAïŒã®èç©éã«åãŒãããã·ã³æäžã®
圱é¿ã調ã¹ãããã®å®éšã¯ãããããã·ãïŒè³è
é«æ¶²ããã®ææ©é žã®éžåºãé²æ¢ããååç©ïŒã¹ã
ã¯ã¿ãŒããã³ããŒã¬ã³ãŸãŒã1974幎ïŒãŸãã¯ãã
ããªããŒã«ïŒäžæ¢ãããããŒãžã³ã¯ã¬ã»ãã¿ãŒã
éå¡ããäœçšãæããå»è¬ïŒãŠã³ã¬ãŒã¹ããã
çã1969幎ïŒã§ååŠçãããè©Šéšåç©ãçšããŠè¡
ã€ããè³å ã®ããã·ã³ã®éãå¢å ãããããšã«ã
ããããããªããŒã«åŠçåç©ã§ã¯è³å ã®HVAè
ç©ãä¿é²ãããããããããã·ãåŠçåç©ã§ã¯è©²
HVAèç©ã¯ä¿é²ãããªãã€ãã äœé150â200ïœã®ãªã¹ã®ã¹ãã©ã°ãŒâããŠã¬ãŒ
ã©ããããã€ãŒã«ããªããŒãããªãŒãžã³ã°ãã©ã
ã©ããªãŒãºïŒãŠã€ã«ãã³ã°ãã³ãMAïŒããäŸçµŠ
ããããã®ãã«ååïŒæããååŸïŒæãŸã§ã®éã
å ç·ç §å°ãè¡ããããã¿ã©ã€ããïŒãºããŠãŒãã¹
ããã³ã³ãããŒïŒããŒã¹ãããŒã²ã³ãN.J.ïŒè£œã®
ãã®ãããããŠãããã°ãã¬ãããã©ããããã€
ãŠãïŒãã€ãŒã«ã¹ããªããŒãããªãŒãžã³ã°ãã©ã
ã©ããªãŒè£œã®é£Œæãããã³æ°Žãèªç±ã«äžãããè¬
åã¯è ¹èå ã«ïŒmlïŒKgïŒäœéïŒã®æ³šå°éïŒå®¹ç©ïŒ
ã§æ³šå°ãããããããªããŒã«ãšããŠãå¯æº¶æ§ãã
ããªããŒã«è£œå€ãããã¯ãã€ã«ãã©ãã©ããªãŒãº
ïŒã©ããžãšã©ãCAïŒè£œã®ããã«ããŒã«ãããæäž
ãããããã·ã³ããã³ããããã·ããã·ã°ããã±
ãã«ã«ãã³ã³ãããŒïŒã»ã³ãã«ã€ã¹ãMOïŒè£œã®
ãã®ãã¯1NâNaOHã«æº¶è§£ãããããŠãPH10.0
ã«èª¿ç¯ããã察象åç©ã«ã¯ãæå®ã®åžéå€ã®ã¿ã
æäžãããããã·ã³ïŒ100mgïŒKgïŒãŸãã¯ãã®åž
éç©ã泚å°ããŠãã20ååŸã«ããã®åç©ã«ããã
ãªããŒã«ïŒïŒmgïŒKgïŒãŸãã¯ããããã·ãïŒ200
mgïŒKgïŒãæäžããã70ååŸã«ãã®åç©ãéŠéšå
æã«ãã殺ãããè³ãéããã«é€å»ããç·ç¶äœ
ïŒã¹ããªã¢ã¿ïŒãåéããŠååºãïŒã°ããŠã€ã³ã¹
ããŒããã³ã€ããŒãœã³ã®æ¹æ³ã1966幎ïŒããã©ã€
ã¢ã€ã¹ã§åçµããã次ãã§HVAãå®éãããæ®
ãã®è³ã®ãã¢ãžããŒããçšããŠããã·ã³ãå®éã
ãïŒã¯ãŒã«ãŒããã³ãŠãŒãã³ãã¬ã³ãã®æ¹æ³ã
1957幎ïŒãåèšã®æ®åè³ãã¢ãžããŒãè©Šæäžã®ã
ãã·ã³ã®æ¿åºŠãåèšç·ç¶äœã®ãã¢ãžããŒãäžã®ã
ãã·ã³ã®æ¿åºŠãšåæ§ãªå€ã§ãããã©ããã確èªã
ãããã«ãåã°ã«ãŒãããã®ïŒå¹ã®åŠçåç©ïŒã
ã®ãã¡ã®è¥å¹²ã®åç©ã¯ãããã·ã³ããã³ïŒãŸãã¯
ããããªããŒã«ãæäžãããã®ã§ãã€ãïŒã«ã€ã
ãŠæ¯èŒãããšãããããã·ã³æ¿åºŠã®å®è³ªçãªå·®ç°
ã¯å šãèŠåºãããªãã€ãã ããã·ã³ããããã·ã©ãŒãŒã®æŽ»æ§ã¯ããŠãšã€ã
ã€ã¢çã®æ¹æ³ïŒ1971幎ïŒã®å€æ³ã«åŸã€ãŠèª¿ã¹ãã
ããªãã¡ãç·ç¶äœããã®10åéïŒå®¹ç©åäœïŒã®
0.05Mâããªã¹ã¢ã»ããŒãç·©è¡æ¶²ïŒPH6.0ïŒã®äž
ã§ãã¢ãžãã€ãºããããã®ç·©è¡æ¶²ã¯ãããªãã³â
â100ããããŒã¬ã³ç€ŸïŒãã€ã©ãã«ãã€ã¢ã
PAïŒãã0.2ïŒ å«ããã®ã§ãã€ããããããŠåŸã
ãããã¢ãžããŒãã«é å¿åé¢æäœã10000ïœã«ã
ããŠ10åéè¡ã€ãããã®äžæŸæ¶²ãéããŠå®éåæ
ãè¡ã€ãïŒã³ã€ã«ã®æ¹æ³ã1972幎ïŒããã®å Žåã®
å®éçšåªè³ªã®å šå®¹ç©ã¯110ÎŒã§ããããããŠã
ã®äžã«æ¬¡ã®ãã®ãå«ãŸããŠãããïŒäžæŸæµäœ50ÎŒ
ïŒDMPH4ïŒããªãã¡ïŒâã¢ããâïŒâããã
ãã·âïŒïŒïŒâãžã¡ãã«âïŒïŒïŒïŒïŒïŒïŒâãã
ã©ããããããªãžã³ãã€ããã¯ãã©ã€ãïŒãã«ã«
ãã€ãªã±ã 瀟ïŒãµã³ãžãšãŽãCAïŒè£œã®ãã®ã
65nmolïŒããªãããµã«ãã¹ããšãŒã29ããã¢
ã«ïŒïŒâã¡ã«ã«ãããšã¿ããŒã«ïŒããã¢ã«ïŒã«ã¿
ã©ãŒãŒ240ãŠãããïŒãã¹ããšãŒãç·©è¡æ¶²ïŒPH
6.2ïŒ0.01ããªã¢ã«ïŒãã¿ã®è èãã調補ããã
è³éŠæâã¢ããé žãã«ã«ããã·ã©ãŒãŒïŒã³ã€
ã«ã1972幎ïŒ10ÎŒïŒè©Šæã¯37âã«ãããŠïŒåé
ãã¬ã€ã³ããŠããŒãããã æçµæ¿åºŠ0.1ïœïŒã®å®éçšåªè³ªã«ïŒ¬âïŒâ 14C
âããã·ã³ïŒæ¯æŽ»æ§åºŠ0.90ÎŒCiïŒïœmolïŒ10ÎŒã
æ·»å ãããããŠãã®è©Šæã37âã«ãããŠ30åéã€
ã³ããŠããŒãããããšã«ããåå¿ãéå§ãããã
ãã®å®éã10ïŒ ããªã¯ããé ¢é ž0.5mlã®æ·»å ã«ã
ãåæ¢ããããã®é žæ§ååªè³ªãå ¶åŸã«ïŒæéãšã
ãšãã㊠14CO2ãååããããã® 14CO2ã¯ã
NCSâçµç¹æº¶è§£å€0.2mläžã«çœ®ãããçŽçïŒæ
ãéãããã®ïŒã«ãã©ããããããåèšæº¶è§£å€ã¯
ã¢ããŒã·ã€ã ïŒãµãŒã«ïŒã¢ãŒãªã³ã°ãã³ããã€
ããILïŒè£œã®ãã®ã§ãã€ãã次ãã§ãã®çŽç
ããã¢ã¯ã¢ãŸã«10mlãå«ãã·ã³ãã¬ãŒã·ãšã³ãã€
ã¢ã«ãããŠãŒãã€ã³ã°ã©ã³ããããŠã¯ãªã¢ç€ŸïŒã
ã¹ãã³ãMAïŒè£œã®ãã®ãã«ç§»ããŠãã®æŸå°èœã
枬å®ããããã©ã³ã¯ïŒç©ºè©ŠéšïŒã§ã¯ã沞隰äžæŸæ¶²
ãŸãã¯ã¢ããšãŒãããã·ã³ïŒ0.2ïœïŒïŒãå«ãå®
å šå®éæ··åç©ã䜿çšãããäž¡æ¹ã®æ¹æ³ã«ãããŠã
åæ§ãªçµæãåŸãããã ããã·ã³æäžã«ãããããããªããŒã«åŠçã©ã
ãã®ç·ç¶äœå ã®HVAèç©éãèããå¢å ãã
ïŒ59ïŒ å¢å ïŒïŒ°ïŒ0.001ïŒïŒç¬¬ïŒå³ïŒãããããªã
ããããããã·ãåŠçåç©ã®å Žåã«ã¯ãè³å ã®ã
ãã·ã³ã®éãåœéå€ãŸã§å¢å€§ãããå Žåã§ããã
HVAèç©éã¯å€åããªãã€ãïŒç¬¬ïŒå³ïŒããã
ããªããŒã«ãæäžããã©ããã§ã¯ãç·ç¶äœå ã®
HVAã®æ¿åºŠãšè³å ã®ããã·ã³ã®æ¿åºŠãšã®éã«å¯
æ¥ãªçžé¢é¢ä¿ãèªããããïŒïœïŒ0.70ïŒïŒ°ïŒ
0.01ïŒïŒç¬¬ïŒå³ïŒãäžæ¹ãããããã·ããæäžãã
åç©ã§ã¯ããã®ãããªçžé¢é¢ä¿ã¯å šãèªããããª
ãã€ãã ããããã·ããæäžããã©ããã§ã¯è³å ã®ãã
ã·ã³ã®éãå€åãããããšã«ããHVAãèç©ã
ãããšïŒããã³ãããã«ãã€ãŠãããã³ãçæã
ããããšïŒã¯ã§ããªããããã®ããšããããã®å Ž
åã«ã¯ã¬ã»ãã¿ãŒäŒéåãã€ãŒãããã¯æ©æ§ãäœ
åããŠããã®ããã«ç·ç¶äœå ã®ãããã³ã¬ã»ãã¿
ãŒã®æŽ»æ§åæ©æ§ããããã³åææå¶æ©æ§ãšçµã³ã€
ãããã«ãHVAã®èç©ããã³ãããã³ã®çæã¯
è¡ãããªãã®ã§ãããšæãããã ããªãã¡ããã®å Žåã«ã¯ããã·ã³æäžã«ããã
ããããã·ãæäžåç©ã®ç·ç¶äœã®åæéããã³æŸ
åºéãæåã®ãã¡ã¯å¢å€§ããããå ¶åŸã«ãããã³
ã¬ã»ãã¿ãŒã®æŽ»æ§ãå¢å€§ãããã®ãã€ãŒãããã¯
äœçšã«ãããããã³ã®çæéãæžå°ãããã®ãã
ãã³çæéã®äœäžãHAVã®çæéã®äœäžãæã
ã®ã§ãããšæããããäžæ¹ãããããªãŸãŒã«åŠç
åç©ã§ã¯äžèšã®ãã€ãŒãããã¯æ©æ§ïŒãã ããã
ã®æ©æ§ã¯æšå®æ©æ§ã§ããïŒãäœåããããã®ãã
ã«ããã·ã³ã®éããããã³ã®åæéã«åœ±é¿ãäž
ãããã®åœ±é¿ã¯çµ¶ããç¶ãããããã³ã®æŸåºãä¿
é²ãããåŸã§ããäžèšã®åœ±é¿ã絶ããç¶ãã®ã§ã
ããšæãããã ããããã·ãåŠçã©ããã§ã¯ãããã·ã³ããã
ãã·ã©ãŒãŒã®åååŠçæ§è³ªïŒkinetic propertiesïŒ
ã®ããŒãããã¯åå€åããã€ãããã«ãããã·ã³
æäžãç·ç¶äœå ã®HVAã®èç©ããããããªãã®
ã§ãããšãã仮説ã®çåœã確èªããããã«ãæã
ã¯ãæã ã®å®éšã°ã«ãŒãã®åã ããæäŸãããå
ç©è³è©Šæã«ã€ããŠãããã·ã³ããã³ãã®ãããªã³
âã³ãã¢ã¯ã¿ãŒã«å¯Ÿããåèšé µçŽ ã®èŠªåæ§ã調ã¹
ããè©Šéšç®¡è©Šéšã§ã¯ãããã·ã³ã®åæïŒpriorïŒ
æäžã¯ãDMPH4ã®ããã·ã³ã«å¯Ÿããããã·ã³ã
ãããã·ã©ãŒãŒã®Kmsã¯åœ±é¿ãäžããªãã€ãã
æ¢è¿°ã®åŠãïŒãžãã³ããã¯çã1974幎ïŒãžãã³ã
ãã¯ããã³ã°ã€ãããã1974幎ïŒãããããªããŒ
ã«ã®æäžã¯DMPH4ã«å¯Ÿããè©²é µçŽ ã®Kmã®äœäž
ããããããã®ã§ãããïŒç¬¬è¡šïŒã 第ïŒå³ã¯ãããããªããŒã«ãŸãã¯ããããã·ã
ãæäžããã©ããã®ç·ç¶äœäžã®HVAèç©éã«å
ãŒãããã·ã³æäžã®åœ±é¿ãå ·äœçã«ç€ºãããã®ã§
ãããã©ããã«ããã·ã³ïŒ100mgïŒKgïŒãŸãã¯ã
ã®åžéå€ãæäžãããã®20ååŸã«ããããªããŒã«
ïŒïŒmgïŒKgïŒãŸãã¯ããããã·ãïŒ200mgïŒKgïŒã
æäžãã第ïŒåç®ã®æ³šå°ãè¡ã€ãŠãã70ååŸã«ã
ã®ã©ããã殺ããåææäœãè¡ãããã®çµæã第
ïŒå³ã®ã°ã©ãã«ç€ºããã第ïŒå³ã«ã¯ãããããªã
ãŒã«ãæäžããè©Šéšåç©ã®ããŒã¿ãŒã¯çœäžžã§ç€º
ããããããªããŒã«ãšããã·ã³ãšã®äž¡è ãæäžã
ãè©Šéšåç©ã®ããŒã¿ãŒã¯é»äžžã§ç€ºãããããããª
ããŒã«ãæäžãããã¹ãŠã®è©Šéšåç©ã§ã¯ãç·ç¶äœ
å ã®HVAã®éãšè³å ã®ããã·ã³ã®éãšã®éã«å¯
æ¥ãªçžé¢é¢ä¿ãèªããããïŒïœïŒ0.70ïŒïŒ°ïŒ
0.01ïŒããããšã¯å¯Ÿç §çã«ãããããã·ãã®ã¿ã
æäžããè©Šéšåç©ïŒïœïŒ17ïŒã®ç·ç¶äœå ã®HVA
ã®éã¯ãããããã·ããšããã·ã³ãšã®äž¡è ãæäž
ããè©Šéšåç©ïŒïœïŒ11ïŒã«ãããHVAã®éãšå€§
äœåãã§ãã€ããåã°ã«ãŒãã«ãããè³å ã®ãã
ã·ã³æ¿åºŠããã³ç·ç¶äœäžã®HVAæ¿åºŠã¯ãããã
次ã®éãã§ãã€ãïŒããããã·ãæäžã°ã«ãŒã
17.65±1.33ÎŒïœïŒïœããã³1.30±0.10ÎŒïœïŒïœïŒã
ãããã·ãïŒããã·ã³æäžã°ã«ãŒã44.06±3.91ÎŒ
ïœïŒïœããã³1.31±0.11ÎŒïœïŒïœïŒããããªããŒ
ã«æäžã°ã«ãŒã17.03±0.97ÎŒïœïŒïœããã³2.00±
0.10ÎŒïœïŒïœïŒããããªããŒã«ïŒããã·ã³æäžã°
ã«ãŒã36.02±2.50ÎŒïœïŒïœããã³3.19±0.20ÎŒïœïŒ
ïœã
ã®ã°ã«ãŒãã®ã©ãããïŒæ©äžé£Œæãäžããã次ã
ã§è©Šéšé£Œæã®ãã¡ã®ïŒã€ãåå10æã«äžãããå
å11æããããã®è©Šéšåç©ãïŒâã®å¯å·ç°å¢ã®å®€
ã«ïŒæéå ¥ãããæ£åã«ãã®è©Šéšåç©ã殺ããã
ã®è³å šäœãåæããŠããã·ã³ããã³MOPEGâ
SO4ã®éã枬å®ãããå®éšã§ã¯ãè©Šéšåç©ã¯ç¡
èçœè³ªé£ŒæãŸãã¯40ïŒ èçœè³ªé£Œæããããã9.7
ïœãŸãã¯10.5ïœæ¶è²»ããå®éšã«ããããããã®
飌æã®æ¶è²»éã¯ãããã6.2ïœãŸãã¯8.0ïœã§ãã€
ãããã®ããŒã¿ã¯ã±SEMã®å¹³åå€ãšããŠç®åºã
ãããã®ã§ãã€ãã äŸ ãã®å®æœäŸã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãããšã«ããè³å ã®ãããã³æŸåºéãå¢å ã§ãã
ããšãäŸç€ºãããã®ã§ããã ãã®ããã·ã³ã®ååšéã®å€å°ãã«ãã³ãŒã«ã¢ã
ã³ç¥çµäŒéç©è³ªã®ã·ããã¹å æŸåºéã«åœ±é¿ãäžã
ããã®ã§ãããã©ãããã¿ãããã«ãè©Šéšåç©ã®
è³å ã«ããããããã³ä»£è¬ç£ç©ã§ãããã¢ãããª
ã³é žïŒHVAïŒã®èç©éã«åãŒãããã·ã³æäžã®
圱é¿ã調ã¹ãããã®å®éšã¯ãããããã·ãïŒè³è
é«æ¶²ããã®ææ©é žã®éžåºãé²æ¢ããååç©ïŒã¹ã
ã¯ã¿ãŒããã³ããŒã¬ã³ãŸãŒã1974幎ïŒãŸãã¯ãã
ããªããŒã«ïŒäžæ¢ãããããŒãžã³ã¯ã¬ã»ãã¿ãŒã
éå¡ããäœçšãæããå»è¬ïŒãŠã³ã¬ãŒã¹ããã
çã1969幎ïŒã§ååŠçãããè©Šéšåç©ãçšããŠè¡
ã€ããè³å ã®ããã·ã³ã®éãå¢å ãããããšã«ã
ããããããªããŒã«åŠçåç©ã§ã¯è³å ã®HVAè
ç©ãä¿é²ãããããããããã·ãåŠçåç©ã§ã¯è©²
HVAèç©ã¯ä¿é²ãããªãã€ãã äœé150â200ïœã®ãªã¹ã®ã¹ãã©ã°ãŒâããŠã¬ãŒ
ã©ããããã€ãŒã«ããªããŒãããªãŒãžã³ã°ãã©ã
ã©ããªãŒãºïŒãŠã€ã«ãã³ã°ãã³ãMAïŒããäŸçµŠ
ããããã®ãã«ååïŒæããååŸïŒæãŸã§ã®éã
å ç·ç §å°ãè¡ããããã¿ã©ã€ããïŒãºããŠãŒãã¹
ããã³ã³ãããŒïŒããŒã¹ãããŒã²ã³ãN.J.ïŒè£œã®
ãã®ãããããŠãããã°ãã¬ãããã©ããããã€
ãŠãïŒãã€ãŒã«ã¹ããªããŒãããªãŒãžã³ã°ãã©ã
ã©ããªãŒè£œã®é£Œæãããã³æ°Žãèªç±ã«äžãããè¬
åã¯è ¹èå ã«ïŒmlïŒKgïŒäœéïŒã®æ³šå°éïŒå®¹ç©ïŒ
ã§æ³šå°ãããããããªããŒã«ãšããŠãå¯æº¶æ§ãã
ããªããŒã«è£œå€ãããã¯ãã€ã«ãã©ãã©ããªãŒãº
ïŒã©ããžãšã©ãCAïŒè£œã®ããã«ããŒã«ãããæäž
ãããããã·ã³ããã³ããããã·ããã·ã°ããã±
ãã«ã«ãã³ã³ãããŒïŒã»ã³ãã«ã€ã¹ãMOïŒè£œã®
ãã®ãã¯1NâNaOHã«æº¶è§£ãããããŠãPH10.0
ã«èª¿ç¯ããã察象åç©ã«ã¯ãæå®ã®åžéå€ã®ã¿ã
æäžãããããã·ã³ïŒ100mgïŒKgïŒãŸãã¯ãã®åž
éç©ã泚å°ããŠãã20ååŸã«ããã®åç©ã«ããã
ãªããŒã«ïŒïŒmgïŒKgïŒãŸãã¯ããããã·ãïŒ200
mgïŒKgïŒãæäžããã70ååŸã«ãã®åç©ãéŠéšå
æã«ãã殺ãããè³ãéããã«é€å»ããç·ç¶äœ
ïŒã¹ããªã¢ã¿ïŒãåéããŠååºãïŒã°ããŠã€ã³ã¹
ããŒããã³ã€ããŒãœã³ã®æ¹æ³ã1966幎ïŒããã©ã€
ã¢ã€ã¹ã§åçµããã次ãã§HVAãå®éãããæ®
ãã®è³ã®ãã¢ãžããŒããçšããŠããã·ã³ãå®éã
ãïŒã¯ãŒã«ãŒããã³ãŠãŒãã³ãã¬ã³ãã®æ¹æ³ã
1957幎ïŒãåèšã®æ®åè³ãã¢ãžããŒãè©Šæäžã®ã
ãã·ã³ã®æ¿åºŠãåèšç·ç¶äœã®ãã¢ãžããŒãäžã®ã
ãã·ã³ã®æ¿åºŠãšåæ§ãªå€ã§ãããã©ããã確èªã
ãããã«ãåã°ã«ãŒãããã®ïŒå¹ã®åŠçåç©ïŒã
ã®ãã¡ã®è¥å¹²ã®åç©ã¯ãããã·ã³ããã³ïŒãŸãã¯
ããããªããŒã«ãæäžãããã®ã§ãã€ãïŒã«ã€ã
ãŠæ¯èŒãããšãããããã·ã³æ¿åºŠã®å®è³ªçãªå·®ç°
ã¯å šãèŠåºãããªãã€ãã ããã·ã³ããããã·ã©ãŒãŒã®æŽ»æ§ã¯ããŠãšã€ã
ã€ã¢çã®æ¹æ³ïŒ1971幎ïŒã®å€æ³ã«åŸã€ãŠèª¿ã¹ãã
ããªãã¡ãç·ç¶äœããã®10åéïŒå®¹ç©åäœïŒã®
0.05Mâããªã¹ã¢ã»ããŒãç·©è¡æ¶²ïŒPH6.0ïŒã®äž
ã§ãã¢ãžãã€ãºããããã®ç·©è¡æ¶²ã¯ãããªãã³â
â100ããããŒã¬ã³ç€ŸïŒãã€ã©ãã«ãã€ã¢ã
PAïŒãã0.2ïŒ å«ããã®ã§ãã€ããããããŠåŸã
ãããã¢ãžããŒãã«é å¿åé¢æäœã10000ïœã«ã
ããŠ10åéè¡ã€ãããã®äžæŸæ¶²ãéããŠå®éåæ
ãè¡ã€ãïŒã³ã€ã«ã®æ¹æ³ã1972幎ïŒããã®å Žåã®
å®éçšåªè³ªã®å šå®¹ç©ã¯110ÎŒã§ããããããŠã
ã®äžã«æ¬¡ã®ãã®ãå«ãŸããŠãããïŒäžæŸæµäœ50ÎŒ
ïŒDMPH4ïŒããªãã¡ïŒâã¢ããâïŒâããã
ãã·âïŒïŒïŒâãžã¡ãã«âïŒïŒïŒïŒïŒïŒïŒâãã
ã©ããããããªãžã³ãã€ããã¯ãã©ã€ãïŒãã«ã«
ãã€ãªã±ã 瀟ïŒãµã³ãžãšãŽãCAïŒè£œã®ãã®ã
65nmolïŒããªãããµã«ãã¹ããšãŒã29ããã¢
ã«ïŒïŒâã¡ã«ã«ãããšã¿ããŒã«ïŒããã¢ã«ïŒã«ã¿
ã©ãŒãŒ240ãŠãããïŒãã¹ããšãŒãç·©è¡æ¶²ïŒPH
6.2ïŒ0.01ããªã¢ã«ïŒãã¿ã®è èãã調補ããã
è³éŠæâã¢ããé žãã«ã«ããã·ã©ãŒãŒïŒã³ã€
ã«ã1972幎ïŒ10ÎŒïŒè©Šæã¯37âã«ãããŠïŒåé
ãã¬ã€ã³ããŠããŒãããã æçµæ¿åºŠ0.1ïœïŒã®å®éçšåªè³ªã«ïŒ¬âïŒâ 14C
âããã·ã³ïŒæ¯æŽ»æ§åºŠ0.90ÎŒCiïŒïœmolïŒ10ÎŒã
æ·»å ãããããŠãã®è©Šæã37âã«ãããŠ30åéã€
ã³ããŠããŒãããããšã«ããåå¿ãéå§ãããã
ãã®å®éã10ïŒ ããªã¯ããé ¢é ž0.5mlã®æ·»å ã«ã
ãåæ¢ããããã®é žæ§ååªè³ªãå ¶åŸã«ïŒæéãšã
ãšãã㊠14CO2ãååããããã® 14CO2ã¯ã
NCSâçµç¹æº¶è§£å€0.2mläžã«çœ®ãããçŽçïŒæ
ãéãããã®ïŒã«ãã©ããããããåèšæº¶è§£å€ã¯
ã¢ããŒã·ã€ã ïŒãµãŒã«ïŒã¢ãŒãªã³ã°ãã³ããã€
ããILïŒè£œã®ãã®ã§ãã€ãã次ãã§ãã®çŽç
ããã¢ã¯ã¢ãŸã«10mlãå«ãã·ã³ãã¬ãŒã·ãšã³ãã€
ã¢ã«ãããŠãŒãã€ã³ã°ã©ã³ããããŠã¯ãªã¢ç€ŸïŒã
ã¹ãã³ãMAïŒè£œã®ãã®ãã«ç§»ããŠãã®æŸå°èœã
枬å®ããããã©ã³ã¯ïŒç©ºè©ŠéšïŒã§ã¯ã沞隰äžæŸæ¶²
ãŸãã¯ã¢ããšãŒãããã·ã³ïŒ0.2ïœïŒïŒãå«ãå®
å šå®éæ··åç©ã䜿çšãããäž¡æ¹ã®æ¹æ³ã«ãããŠã
åæ§ãªçµæãåŸãããã ããã·ã³æäžã«ãããããããªããŒã«åŠçã©ã
ãã®ç·ç¶äœå ã®HVAèç©éãèããå¢å ãã
ïŒ59ïŒ å¢å ïŒïŒ°ïŒ0.001ïŒïŒç¬¬ïŒå³ïŒãããããªã
ããããããã·ãåŠçåç©ã®å Žåã«ã¯ãè³å ã®ã
ãã·ã³ã®éãåœéå€ãŸã§å¢å€§ãããå Žåã§ããã
HVAèç©éã¯å€åããªãã€ãïŒç¬¬ïŒå³ïŒããã
ããªããŒã«ãæäžããã©ããã§ã¯ãç·ç¶äœå ã®
HVAã®æ¿åºŠãšè³å ã®ããã·ã³ã®æ¿åºŠãšã®éã«å¯
æ¥ãªçžé¢é¢ä¿ãèªããããïŒïœïŒ0.70ïŒïŒ°ïŒ
0.01ïŒïŒç¬¬ïŒå³ïŒãäžæ¹ãããããã·ããæäžãã
åç©ã§ã¯ããã®ãããªçžé¢é¢ä¿ã¯å šãèªããããª
ãã€ãã ããããã·ããæäžããã©ããã§ã¯è³å ã®ãã
ã·ã³ã®éãå€åãããããšã«ããHVAãèç©ã
ãããšïŒããã³ãããã«ãã€ãŠãããã³ãçæã
ããããšïŒã¯ã§ããªããããã®ããšããããã®å Ž
åã«ã¯ã¬ã»ãã¿ãŒäŒéåãã€ãŒãããã¯æ©æ§ãäœ
åããŠããã®ããã«ç·ç¶äœå ã®ãããã³ã¬ã»ãã¿
ãŒã®æŽ»æ§åæ©æ§ããããã³åææå¶æ©æ§ãšçµã³ã€
ãããã«ãHVAã®èç©ããã³ãããã³ã®çæã¯
è¡ãããªãã®ã§ãããšæãããã ããªãã¡ããã®å Žåã«ã¯ããã·ã³æäžã«ããã
ããããã·ãæäžåç©ã®ç·ç¶äœã®åæéããã³æŸ
åºéãæåã®ãã¡ã¯å¢å€§ããããå ¶åŸã«ãããã³
ã¬ã»ãã¿ãŒã®æŽ»æ§ãå¢å€§ãããã®ãã€ãŒãããã¯
äœçšã«ãããããã³ã®çæéãæžå°ãããã®ãã
ãã³çæéã®äœäžãHAVã®çæéã®äœäžãæã
ã®ã§ãããšæããããäžæ¹ãããããªãŸãŒã«åŠç
åç©ã§ã¯äžèšã®ãã€ãŒãããã¯æ©æ§ïŒãã ããã
ã®æ©æ§ã¯æšå®æ©æ§ã§ããïŒãäœåããããã®ãã
ã«ããã·ã³ã®éããããã³ã®åæéã«åœ±é¿ãäž
ãããã®åœ±é¿ã¯çµ¶ããç¶ãããããã³ã®æŸåºãä¿
é²ãããåŸã§ããäžèšã®åœ±é¿ã絶ããç¶ãã®ã§ã
ããšæãããã ããããã·ãåŠçã©ããã§ã¯ãããã·ã³ããã
ãã·ã©ãŒãŒã®åååŠçæ§è³ªïŒkinetic propertiesïŒ
ã®ããŒãããã¯åå€åããã€ãããã«ãããã·ã³
æäžãç·ç¶äœå ã®HVAã®èç©ããããããªãã®
ã§ãããšãã仮説ã®çåœã確èªããããã«ãæã
ã¯ãæã ã®å®éšã°ã«ãŒãã®åã ããæäŸãããå
ç©è³è©Šæã«ã€ããŠãããã·ã³ããã³ãã®ãããªã³
âã³ãã¢ã¯ã¿ãŒã«å¯Ÿããåèšé µçŽ ã®èŠªåæ§ã調ã¹
ããè©Šéšç®¡è©Šéšã§ã¯ãããã·ã³ã®åæïŒpriorïŒ
æäžã¯ãDMPH4ã®ããã·ã³ã«å¯Ÿããããã·ã³ã
ãããã·ã©ãŒãŒã®Kmsã¯åœ±é¿ãäžããªãã€ãã
æ¢è¿°ã®åŠãïŒãžãã³ããã¯çã1974幎ïŒãžãã³ã
ãã¯ããã³ã°ã€ãããã1974幎ïŒãããããªããŒ
ã«ã®æäžã¯DMPH4ã«å¯Ÿããè©²é µçŽ ã®Kmã®äœäž
ããããããã®ã§ãããïŒç¬¬è¡šïŒã 第ïŒå³ã¯ãããããªããŒã«ãŸãã¯ããããã·ã
ãæäžããã©ããã®ç·ç¶äœäžã®HVAèç©éã«å
ãŒãããã·ã³æäžã®åœ±é¿ãå ·äœçã«ç€ºãããã®ã§
ãããã©ããã«ããã·ã³ïŒ100mgïŒKgïŒãŸãã¯ã
ã®åžéå€ãæäžãããã®20ååŸã«ããããªããŒã«
ïŒïŒmgïŒKgïŒãŸãã¯ããããã·ãïŒ200mgïŒKgïŒã
æäžãã第ïŒåç®ã®æ³šå°ãè¡ã€ãŠãã70ååŸã«ã
ã®ã©ããã殺ããåææäœãè¡ãããã®çµæã第
ïŒå³ã®ã°ã©ãã«ç€ºããã第ïŒå³ã«ã¯ãããããªã
ãŒã«ãæäžããè©Šéšåç©ã®ããŒã¿ãŒã¯çœäžžã§ç€º
ããããããªããŒã«ãšããã·ã³ãšã®äž¡è ãæäžã
ãè©Šéšåç©ã®ããŒã¿ãŒã¯é»äžžã§ç€ºãããããããª
ããŒã«ãæäžãããã¹ãŠã®è©Šéšåç©ã§ã¯ãç·ç¶äœ
å ã®HVAã®éãšè³å ã®ããã·ã³ã®éãšã®éã«å¯
æ¥ãªçžé¢é¢ä¿ãèªããããïŒïœïŒ0.70ïŒïŒ°ïŒ
0.01ïŒããããšã¯å¯Ÿç §çã«ãããããã·ãã®ã¿ã
æäžããè©Šéšåç©ïŒïœïŒ17ïŒã®ç·ç¶äœå ã®HVA
ã®éã¯ãããããã·ããšããã·ã³ãšã®äž¡è ãæäž
ããè©Šéšåç©ïŒïœïŒ11ïŒã«ãããHVAã®éãšå€§
äœåãã§ãã€ããåã°ã«ãŒãã«ãããè³å ã®ãã
ã·ã³æ¿åºŠããã³ç·ç¶äœäžã®HVAæ¿åºŠã¯ãããã
次ã®éãã§ãã€ãïŒããããã·ãæäžã°ã«ãŒã
17.65±1.33ÎŒïœïŒïœããã³1.30±0.10ÎŒïœïŒïœïŒã
ãããã·ãïŒããã·ã³æäžã°ã«ãŒã44.06±3.91ÎŒ
ïœïŒïœããã³1.31±0.11ÎŒïœïŒïœïŒããããªããŒ
ã«æäžã°ã«ãŒã17.03±0.97ÎŒïœïŒïœããã³2.00±
0.10ÎŒïœïŒïœïŒããããªããŒã«ïŒããã·ã³æäžã°
ã«ãŒã36.02±2.50ÎŒïœïŒïœããã³3.19±0.20ÎŒïœïŒ
ïœã
ãè¡šã
第衚èšèŒã®ããŒã¿ãŒã¯ã次ã®å®éšã®çµæã瀺
ãããã®ã§ãããããªãã¡ããã·ã³ããããã·ã©
ãŒãŒã®æŽ»æ§ã調ã¹ãããã«ç·ç¶äœè©Šæã®å®éãã
ããã·ã³æ¿åºŠã0.125â1.0ïœïŒãšããŠãããŠ
DMPH4æ¿åºŠã0.1â0.5ïœïŒãšããŠè¡ã€ãã®ã§ã
ããããããªããŒã«ãããã·ã³ãšäžç·ã«ããŸãã¯
äžç·ã«ããã«æäžããè©Šéšåç©ã®å Žåã«ã¯ããã
ããã·ããæäžããè©Šéšåç©ã®å Žåãããã
DMPH4ã«å¯Ÿããããã·ã³ããããã·ã©ãŒãŒã®
Kmã®å€ãèããäœãã€ãïŒïŒ°ïŒ0.001ïŒæ¬ç 究è
ã®ïœâãã¹ãïŒã ããã«ããããã®ããŒã¿ãŒã¯æ¬¡ã®ä»®èª¬ã®æ£åœæ§
ãæ¯æãããã®ã§ãããããªãã¡ãããã·ã³ãã
ããã·ã©ãŒãŒã¯åžžã«çäœäžã§ãã®ã¢ããé žåºè³ªã§
飜åããåŸããã®ã§ã¯éãããæèšããã°ãïŒã
ãããªããŒã«ã«ããïŒããŒããã³âã¬ã»ãã¿ãŒã®
éå¡ïŒé®æïŒã®çµæãšããŠããããã³ãéåžžã®å Ž
åãããäžå±€å€ãåæãããããªè³ãæããåç©
ã§ã¯ãããã·ã³ããããã·ã©ãŒãŒã¯åžžã«çäœäžã®
ãã®ã¢ããé žåºè³ªã§é£œåããåŸããã®ãšã¯éããª
ããšãã仮説ã¯æ£åœã§ãããšæããããããã«ãŸ
ããåèšã®ããŒã¿ãã次ã®ããšã容æã«ç解ãã
åŸãã§ããããããªãã¡ãïŒããã·ã³æäžã«ããïŒ
åèšé µçŽ ã®é£œå床ãäžå±€é«ããããšã«ãããã
ããã«ãã³ãŒã«ã¢ãã³ç¥çµäŒéç©è³ªããã³ããã
ã³ã®çæéã®ã¿ãªãã該äŒéç©è³ªã®æŸåºéããŸã
äžå±€å¢å€§ã§ããã®ã§ãããããã·ã³ã«ããããã
ã³ã®åæããã³æŸåºãå¶åŸ¡ããããšã«ãã次ã®ç
æ°ãæ²»çã§ããããªãã¡ããã«ããªããŒã«æäžåŸ
ã®ããŒãã³ãœã³ç ã®åŠãããããããŒãžãã¯ãã€
ãã³ã®è奮ããã°ãã°èµ·ãç æ°ãæ²»çã§ããã®ã§
ããã äŸ ãã®å®æœäŸã¯ãåç©ã®è¡æž äžã®ããã©ã¯ãã³ã®
éãæžå°ãããããã«ã¯ãããã·ã³ã®æäžãæå©
ã§ããããšãäŸç€ºãããã®ã§ããã è€æ°ã®ã°ã«ãŒãã®ãªã¹ã®ã©ããïŒïŒã°ã«ãŒãã¯
ïŒå¹ãããªãïŒã«ã¬ã»ã«ãã³ãè ¹èå ã«ïŒæ¥éã«
ããã€ãŠæäžãããæäžéã¯2.5mgïŒKgïŒæ¥ã§ã
ã€ãŠãïŒæ¥åã®æäžéãïŒçåããŠãïŒåã«åã
ãŠæäžãããïŒæ¥ç®ã®æã¯ã¬ã»ã«ãã³ãæäžãã
ã«ãã®ä»£ãã«ãå šäœã®ååã®è©Šéšåç©ã«ããã·ã³
ïŒ200mgïŒKgïŒãæäžããæ®ãã®ååã«ã¯ããã¯ã«
ïŒé£å¡©æ°ŽïŒã®ã¿ãæäžããïŒæéåŸã«æ®ºãããè¡
æž ãéããŠãæŸå°ç·ãçšããå ç«åŠçå®éæ³ã«ã
ãããã©ã¯ãã³ãå®éãããåŸãããå®éšããŒã¿
ãŒã次衚ã«ç€ºãã
ãããã®ã§ãããããªãã¡ããã·ã³ããããã·ã©
ãŒãŒã®æŽ»æ§ã調ã¹ãããã«ç·ç¶äœè©Šæã®å®éãã
ããã·ã³æ¿åºŠã0.125â1.0ïœïŒãšããŠãããŠ
DMPH4æ¿åºŠã0.1â0.5ïœïŒãšããŠè¡ã€ãã®ã§ã
ããããããªããŒã«ãããã·ã³ãšäžç·ã«ããŸãã¯
äžç·ã«ããã«æäžããè©Šéšåç©ã®å Žåã«ã¯ããã
ããã·ããæäžããè©Šéšåç©ã®å Žåãããã
DMPH4ã«å¯Ÿããããã·ã³ããããã·ã©ãŒãŒã®
Kmã®å€ãèããäœãã€ãïŒïŒ°ïŒ0.001ïŒæ¬ç 究è
ã®ïœâãã¹ãïŒã ããã«ããããã®ããŒã¿ãŒã¯æ¬¡ã®ä»®èª¬ã®æ£åœæ§
ãæ¯æãããã®ã§ãããããªãã¡ãããã·ã³ãã
ããã·ã©ãŒãŒã¯åžžã«çäœäžã§ãã®ã¢ããé žåºè³ªã§
飜åããåŸããã®ã§ã¯éãããæèšããã°ãïŒã
ãããªããŒã«ã«ããïŒããŒããã³âã¬ã»ãã¿ãŒã®
éå¡ïŒé®æïŒã®çµæãšããŠããããã³ãéåžžã®å Ž
åãããäžå±€å€ãåæãããããªè³ãæããåç©
ã§ã¯ãããã·ã³ããããã·ã©ãŒãŒã¯åžžã«çäœäžã®
ãã®ã¢ããé žåºè³ªã§é£œåããåŸããã®ãšã¯éããª
ããšãã仮説ã¯æ£åœã§ãããšæããããããã«ãŸ
ããåèšã®ããŒã¿ãã次ã®ããšã容æã«ç解ãã
åŸãã§ããããããªãã¡ãïŒããã·ã³æäžã«ããïŒ
åèšé µçŽ ã®é£œå床ãäžå±€é«ããããšã«ãããã
ããã«ãã³ãŒã«ã¢ãã³ç¥çµäŒéç©è³ªããã³ããã
ã³ã®çæéã®ã¿ãªãã該äŒéç©è³ªã®æŸåºéããŸã
äžå±€å¢å€§ã§ããã®ã§ãããããã·ã³ã«ããããã
ã³ã®åæããã³æŸåºãå¶åŸ¡ããããšã«ãã次ã®ç
æ°ãæ²»çã§ããããªãã¡ããã«ããªããŒã«æäžåŸ
ã®ããŒãã³ãœã³ç ã®åŠãããããããŒãžãã¯ãã€
ãã³ã®è奮ããã°ãã°èµ·ãç æ°ãæ²»çã§ããã®ã§
ããã äŸ ãã®å®æœäŸã¯ãåç©ã®è¡æž äžã®ããã©ã¯ãã³ã®
éãæžå°ãããããã«ã¯ãããã·ã³ã®æäžãæå©
ã§ããããšãäŸç€ºãããã®ã§ããã è€æ°ã®ã°ã«ãŒãã®ãªã¹ã®ã©ããïŒïŒã°ã«ãŒãã¯
ïŒå¹ãããªãïŒã«ã¬ã»ã«ãã³ãè ¹èå ã«ïŒæ¥éã«
ããã€ãŠæäžãããæäžéã¯2.5mgïŒKgïŒæ¥ã§ã
ã€ãŠãïŒæ¥åã®æäžéãïŒçåããŠãïŒåã«åã
ãŠæäžãããïŒæ¥ç®ã®æã¯ã¬ã»ã«ãã³ãæäžãã
ã«ãã®ä»£ãã«ãå šäœã®ååã®è©Šéšåç©ã«ããã·ã³
ïŒ200mgïŒKgïŒãæäžããæ®ãã®ååã«ã¯ããã¯ã«
ïŒé£å¡©æ°ŽïŒã®ã¿ãæäžããïŒæéåŸã«æ®ºãããè¡
æž ãéããŠãæŸå°ç·ãçšããå ç«åŠçå®éæ³ã«ã
ãããã©ã¯ãã³ãå®éãããåŸãããå®éšããŒã¿
ãŒã次衚ã«ç€ºãã
ãè¡šã
äžè¡šäžã®ããŒã¿ãŒã¯ãå¹³åå€Â±æšæºèª€å·®ã®åœ¢ã§
è¡šããããã®ã§ããã ïŒïŒ°ïŒ0.005ïŒããã¯ã«ã®ã¬ãã«ãšæ¯èŒããå€ïŒã äžèšã®å®éšçµæããæãããªããã«ãããã·ã³
ã®æäžã«ããè¡æž äžã®ããã©ã¯ãã³ã®éãæžå°ã
ãã®ã§ããããããã«ã人äœã«ãããŠè¡æž äžã®ã
ãã©ã¯ãã³ã®éãå€ãå Žåã«ã¯ããã®ã¢ããé žã®
æäžã«ããã該ããã©ã¯ãã³ã®éãå ·åããæžå°
ãããããšãã§ããããã®æ²»çæ³ã¯ãããçšãã
æ²»çæ³ãããäžå±€æãŸãããã®ã§ããããªããªã
ã°ãããã¯äœå ã®ãã¹ãŠã®çŽ°èã«ãããŠãããã³
ã«å€æããããã®ã§ããããã«ãå€ãã®å¯äœçšã
æããããã§ãããããã«å¯Ÿãããã·ã³ã¯ããã®
äŒéç©è³ªïŒããªãã¡ããã·ã³ïŒãéåžžçæãã现
èïŒããã¯äœå ããã³è³å ã«ååšããïŒã®äžã§ã
ããããã³ã«å€æãããªãã®ã§ãããã·ã³ã¯å®è³ª
çãªå¯äœçšã¯å šãæããªãã
è¡šããããã®ã§ããã ïŒïŒ°ïŒ0.005ïŒããã¯ã«ã®ã¬ãã«ãšæ¯èŒããå€ïŒã äžèšã®å®éšçµæããæãããªããã«ãããã·ã³
ã®æäžã«ããè¡æž äžã®ããã©ã¯ãã³ã®éãæžå°ã
ãã®ã§ããããããã«ã人äœã«ãããŠè¡æž äžã®ã
ãã©ã¯ãã³ã®éãå€ãå Žåã«ã¯ããã®ã¢ããé žã®
æäžã«ããã該ããã©ã¯ãã³ã®éãå ·åããæžå°
ãããããšãã§ããããã®æ²»çæ³ã¯ãããçšãã
æ²»çæ³ãããäžå±€æãŸãããã®ã§ããããªããªã
ã°ãããã¯äœå ã®ãã¹ãŠã®çŽ°èã«ãããŠãããã³
ã«å€æããããã®ã§ããããã«ãå€ãã®å¯äœçšã
æããããã§ãããããã«å¯Ÿãããã·ã³ã¯ããã®
äŒéç©è³ªïŒããªãã¡ããã·ã³ïŒãéåžžçæãã现
èïŒããã¯äœå ããã³è³å ã«ååšããïŒã®äžã§ã
ããããã³ã«å€æãããªãã®ã§ãããã·ã³ã¯å®è³ª
çãªå¯äœçšã¯å šãæããªãã
第ïŒå³ã¯å®æœäŸèšèŒã®å®éšã®çµæã瀺ããã°
ã©ãã§ããã第ïŒå³ã¯å®æœäŸèšèŒã®å®éšã®çµæ
ã瀺ããã°ã©ãã§ããã
ã©ãã§ããã第ïŒå³ã¯å®æœäŸèšèŒã®å®éšã®çµæ
ã瀺ããã°ã©ãã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ è¡æž äžã®ããã©ã¯ãã³ã®éãäœäžãããçµæ
ç©ã«ãããŠãããã·ã³ãããšãã«ã¢ã©ãã³ããŸã
ã¯ããã·ã³ãšããšãã«ã¢ã©ãã³ãšã®æ··åç©ãçŽïŒ
â200mgïŒKgïŒäœéïŒå«ãã¢ããé žè£œå€ãå«æã
ãããšãç¹åŸŽãšããçµæç©ã ïŒ ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã«ãã
ãŠã (ã€) è¡æž äžã®ããã©ã¯ãã³ã®éãå¢å ãããè¬å€
ãšã (ã) ããã·ã³ãããšãã«ã¢ã©ãã³ããŸãã¯ããã·
ã³ãšããšãã«ã¢ã©ãã³ãšã®æ··åç©ãçŽïŒâ200
mgïŒKgïŒäœéïŒå«æããäžæ§ã¢ããé žè£œå€ ãšãå«æããããšãç¹åŸŽãšããçµæç©ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89874078A | 1978-04-24 | 1978-04-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS557261A JPS557261A (en) | 1980-01-19 |
| JPS6326086B2 true JPS6326086B2 (ja) | 1988-05-27 |
Family
ID=25409977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4983079A Granted JPS54145219A (en) | 1978-04-24 | 1979-04-24 | Composition for increasing dopamine and norepinephilin content within neurosynapse |
| JP4983279A Granted JPS557261A (en) | 1978-04-24 | 1979-04-24 | Composition of decreasing quantity of prolactin in serum |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4983079A Granted JPS54145219A (en) | 1978-04-24 | 1979-04-24 | Composition for increasing dopamine and norepinephilin content within neurosynapse |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0005058B1 (ja) |
| JP (2) | JPS54145219A (ja) |
| CA (1) | CA1140859A (ja) |
| DE (1) | DE2967257D1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE30210T1 (de) * | 1981-07-15 | 1987-10-15 | Richard J Wurtman | Zusammensetzung zur erhoehung des blutdrucks. |
| US4542123A (en) * | 1982-01-11 | 1985-09-17 | Massachusetts Institute Of Technology | Composition and method for increasing brain tyrosine levels |
| ATE45672T1 (de) * | 1983-05-16 | 1989-09-15 | Massachusetts Inst Technology | Eine pharmazeutische zusammensetzung zum zweck der behandlung einer neurologischen krankheit oder des alterns. |
| JP2601865Y2 (ja) * | 1993-03-04 | 1999-12-06 | æ¥ç£ãã£ãŒãŒã«å·¥æ¥æ ªåŒäŒç€Ÿ | é»åãã©ãŒã¢ãŒã ã®æ¯æè£ çœ® |
| US5480865A (en) * | 1994-02-25 | 1996-01-02 | Parkinson's Charitable Trust | Nutritional composition |
| JP2004123564A (ja) * | 2002-09-30 | 2004-04-22 | Inst Of Physical & Chemical Res | äžæ¢æ©èœæ¹åçšã¢ããé žçµæç© |
| CN112924598B (zh) * | 2021-01-28 | 2023-07-28 | 广å·åžåŠå¥³å¿ç«¥å»çäžå¿ | çç©èºç±»ç¥ç»é莚çå®éåææ¹æ³ |
| CN117919232B (zh) * | 2023-11-30 | 2024-10-25 | äžæµ·åžäžæ¹å»é¢ïŒåæµå€§åŠéå±äžæ¹å»é¢ïŒ | å²åäžé žåšæ²»çè硬å以åå ç«æ§èæ䌀çåºçš |
-
1979
- 1979-04-20 EP EP79300650A patent/EP0005058B1/en not_active Expired
- 1979-04-20 DE DE7979300650T patent/DE2967257D1/de not_active Expired
- 1979-04-24 JP JP4983079A patent/JPS54145219A/ja active Granted
- 1979-04-24 CA CA000326257A patent/CA1140859A/en not_active Expired
- 1979-04-24 JP JP4983279A patent/JPS557261A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS54145219A (en) | 1979-11-13 |
| EP0005058B1 (en) | 1984-10-17 |
| CA1140859A (en) | 1983-02-08 |
| JPS647044B2 (ja) | 1989-02-07 |
| EP0005058A3 (en) | 1979-11-14 |
| JPS557261A (en) | 1980-01-19 |
| DE2967257D1 (en) | 1984-11-22 |
| EP0005058A2 (en) | 1979-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| van Praag et al. | Cerebral monoamines and depression: an investigation with the probenecid technique | |
| Karoum et al. | Brain concentrations of biogenic amine metabolites in acutely treated and ethanolâdependent rats | |
| Pletscher et al. | Inhibitors of monoamine oxidase and decarboxylase of aromatic amino acids | |
| RU2125448C1 (ru) | ЀаÑЌаÑевÑОÑеÑÐºÐ°Ñ ÐºÐŸÐŒÐ¿ÐŸÐ·ÐžÑÐžÑ Ðž ÑпПÑПб ее пПлÑÑеМОÑ, ÑпПÑПб леÑÐµÐœÐžÑ ÐœÐ°ÑÑÑеМОй, ÑазвОваÑÑÐžÑ ÑÑ Ð²ÑлеЎÑÑвОе МейÑПЎегеМеÑаÑОвМÑÑ Ð¿ÑПÑеÑÑПв | |
| Jacoby et al. | Mechanisms by which quipazine, a putative serotonin receptor agonist, alters brain 5-hydroxyindole metabolism | |
| Aprison et al. | Hypersensitive serotonergic receptors: A new hypothesis for one subgroup of unipolar depression derived from an animal model | |
| JP2000505426A (ja) | ç¥çµçŽ°èæ©èœã®ç¶æããã®æ¶å€±ã®é²æ¢åã¯å埩ã®ããã®ããã¬ãã«ååç©ã®å©çš | |
| Tissot | The common pathophysiology of monoaminergic psychoses: a new hypothesis | |
| JPH0138087B2 (ja) | ||
| JPS6326086B2 (ja) | ||
| Enrico et al. | Effect of morphine on striatal dopamine metabolism and ascorbic acid and uric acid release in freely moving rats | |
| Squires et al. | The inhibition of A and B forms of MAO in the production of a characteristic behavioural syndrome in rats after L-tryptophan loading | |
| EP1572185A1 (en) | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents | |
| US4190672A (en) | Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone | |
| US4435424A (en) | Process for improving vigor and mood in normal human patients | |
| Boulton | Phenylethylaminergic modulation of catecholaminergic neurotransmission | |
| Gelenberg et al. | Tyrosine for the treatment of depression | |
| Squires | EVIDENCE THAT 5âMETHOXYâN, NâDIMETHYL TRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAOâA IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIOURAL SYNDROME | |
| US10456373B2 (en) | Agent exhibiting anti-stress, anxiolytic and anti-depression activity, and composition based thereon | |
| Kabins et al. | Potential Applications for Monoamine Oxidase B Inhibitors. pp 323â334 | |
| AU3999185A (en) | Method of treating memory disorders of the elderly | |
| US4224343A (en) | Process and composition for decreasing blood serum prolactin levels | |
| De Luca Sarobe et al. | Low sodium intake induces an increase in renal monoamine oxidase activity in the rat. Involvement of an angiotensin II dependent mechanism | |
| Sourkes | Cerebral and other diseases with disturbance of amine metabolism | |
| EP0005333A1 (en) | A pharmaceutical composition comprising an amino acid for reducing blood serum prolactin levels |